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ABBREVIATIONS 
 
ADH  atypical ductal hyperplasia 
AKT  v-akt murine thymoma viral oncogene homolog 1 
AMP  adenosine monophosphate 
AMPK  AMP-activted kinase 
ARE  AU-rich element 
ATF2  activating transcription factor 2 
ATM  ataxia telangiectasia mutated 
AngII  angiotensin II 
ATP  adenosine triphosphate 
ATR  ATM and Rad3-related 
AUF1  AU-binding factor 1, also known as hnRNP D 
Bcl-2  B-cell lymphoma 2 
BRCA  breast cancer susceptibility gene 
BRF1  butyrate response factor 1 
CARM1  coactivator-associated arginine methyltransferase 1 
Cdk1  cyclin-dependent kinase 1 
Chk1/2  checkpoint kinase 1/2 
COX-2  cyclooxygenase 2 
CTGF  connective tissue growth factor 
DCIS  ductal carcinoma in situ 
dCK  deoxy-cytidine kinase 
ECM  extracellular matrix 
EGF  epidermal growth factor 
ELAV  embryonic lethal abnormal vision 
EMT  epithelia-to-mesenchymal transition 
GM-CSF  granulocyte macrophage colony-stimulating factor 
HIF-1α  hypoxia-inducible factor 1α 
HNS  HuR nucleocytoplasmic shuttling 
HuB  human antigen B, also known as HelN1 
HuC  human antigen C 
HuD  human antigen D 
HuR  human antigen R, also known as HuA 
IL  interleukine 
IRES  internal ribosomy entry site 
JNK  c-Jun N-terminal kinase 
KSRP  K homology-splicing regulatory protein 
MAPK  mitogen-activated protein kinase 
MCC  Merkel cell carcinoma 
MCF7  breast cancer cell line 
MCT-1  multiple copies in T cell lymphoma 1 
MK2  MAPKAPK2, MAPK-activated protein kinase 2 
MKP-1  MAPK phosphatase-1 
miRNA/miR  microRNA 
MMP  matrix metalloproteinase 
N.D.  not detected / not determined 
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NF90  nuclear factor 90 
P-bodies  processing bodies 
PI3K  phosphoinositide 3-kinase 
PKC  protein kinase C 
pp32/PHAP-1 acidic (leucine-rich) nuclear phosphoprotein 32 family member A 
RAB31  Ras oncogene family member 
RBP  RNA-binding protein 
RCC  renal cell carcinoma 
RISC  ribonucleoacid-induced silencing complex 
RRM  RNA-recognition motif 
SIRT1  sirtuin 1 
TDLU  terminal ductal lobular unit  
TGF-β  tumor growth factor β 
TIA-1  T-cell-restricted intracellular antigen 1 
TIAR  TIA1-related protein 
TNF-α  tumor necrosis factor α 
TNM  tumor-node-metastasis 
TSP1  tumor suppressor and angiogenesis inhibitor 1 
TTP  tristetraproline 
TTR-RBP  turnover and/or translation regulatory RNA-binding protein 
uPA  urokinase 
uPAR  urokinase receptor 
UTR  untranslated region 
UV  ultraviolet 
VEGF  vascular endothelial growth factor 
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ABSTRACT 
 
Breast cancer is the most common cancer among women. Although its prognosis has 
improved nowadays, methods to predict the progression of the disease or to treat it are not 
comprehensive. This thesis work was initiated to elucidate in breast carcinogenesis the role of 
HuR, a ubiquitously expressed mRNA-binding protein that regulates gene expression 
posttranscriptionally. HuR is predominantly nuclear, but it shuttles between the nucleus and 
the cytoplasm, and this nucleocytoplasmic translocation is important for its function as a 
RNA-stabilizing and translational regulator. HuR has been associated with diverse cellular 
processes, for example carcinogenesis. The specific aims of my thesis work were to study the 
prognostic value of HuR in breast cancer and to clarify the mechanisms by which HuR 
contributes to breast carcinogenesis. My ultimate goal is, by better understanding the role of 
HuR in breast carcinogenesis, to aid in the discovery of novel targets for cancer therapies. 
 
HuR expression and localization was studied in paraffin-embedded preinvasive (atypical 
ductal hyperplasia, ADH, and ductal carcinoma in situ, DCIS) specimens as well in sporadic 
and familial breast cancer specimens. Our results show that cytoplasmic HuR expression was 
already elevated in ADH and remained elevated in DCIS as well as in cancer specimens. 
Clinicopathological analysis showed that cytoplasmic HuR expression associated with the 
more aggressive form of the disease in DCIS, and in cancer specimens it proved an 
independent marker for poor prognosis. Importantly, cytoplasmic HuR expression was 
significantly associated with poor outcome in the subgroups of small (< 2 cm) and axillary 
lymph node-negative breast cancers. HuR proved to be the first mRNA stability protein the 
expression of which is associated in breast cancer with poor outcome.  
 
To explore the mechanisms of HuR in breast carcinogenesis, lentiviral constructs were 
developed to inhibit and to overexpress the HuR expression in a breast epithelial cell line 
(184B5Me). Our results suggest that HuR mediates breast carcinogenesis by participating in 
processes important in cell transformation, in programmed cell death, and in cell invasion. 
Global gene expression analysis shows that HuR regulates genes participating in diverse 
cellular processes, and affects several pathways important in cancer development. In addition, 
we identified two novel target transcripts (connective tissue growth factor, CTGF, and Ras 
oncogene family member 31, RAB31) for HuR. 
 
In conclusion, because cytoplasmic HuR expression in breast cancer can predict the outcome 
of the disease it could serve in clinics as a prognostic marker. HuR accumulates in the 
cytoplasm even at its non-invasive stage (ADH and DCIS) of the carcinogenic process and 
supports functions essential in cell alteration. These data suggest that HuR contributes to 
carcinogenesis of the breast epithelium. 
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INTRODUCTION TO THE SUBJECT 
 
1. FEMALE MAMMARY GLAND 
 
The female mammary gland is a unique organ since it fully develops only after puberty and 
undergoes constant remodeling and differentiation during the reproductive phase. Before 
puberty the development of mammary glands does not differ between females and males. 
However, at puberty the female mammary gland starts differentiating under the influence of 
hormones, predominantly estrogen derived from the ovaries. The ducts start to elongate and 
branch, forming a ductal tree with 15 to 25 major ducts (Fridriksdottir et al. 2005), each 
having an opening to the nipple. These main ducts branch further, eventually leading to 
terminal ductal lobular units (TDLUs) which terminates to individual blunt-ending ductuoles 
(acini) forming a lobule (Figure 1) (Howard et al. 2000, Parmar et al. 2004).  
 
 
 
Figure 1. Schematic of a cross-section of a duct and part of a ductal tree ending in a TDLU. 
Immunohistochemical breast tissue stained with Mayer’s hematoxylin and eosin. Original 
magnification is 100x. 
 
 
Acini in TDLUs are responsible for milk secretion during lactation (Gudjonsson et al. 2005). 
Ducts and lobules form from two layers of epithelial cells, an outer layer of basal 
myoepithelial cells and an inner layer of polarized luminal cells separated from the 
surrounding stroma (connective and fat tissue) by a basement membrane (Figure 1) 
(Gudjonsson et al. 2005). Additionally, the luminal epithelial side contains breast epithelial 
Introduction to the Subject 
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progenitor cells, precursors for both types of epithelial cells. These progenitor cells are 
responsible for the continuous renewal, growth, and branching in the breast as a response to 
hormonal and growth factor signals during the normal menstrual cycle, in pregnancy, and at 
postmenopausal involution (Howard et al. 2000, Gudjonsson et al. 2005). 
 
 
2. BREAST CARCINOGENESIS 
 
Breast cancer is the most common cancer among women. In 2009 in Finland 4464 new breast 
cancer cases occurred in women, comprising 32% of all new cancer cases in women 
(www.cancer.fi/syoparekisteri). The worldwide estimate in 2008 was for 12.7 million new 
cancer cases and 7.6 million cancer-related deaths. The most commonly diagnosed cancer was 
pulmonary (12.7%), but breast cancer (10.9%) was in second place (http://globocan.iarc.fr), 
being by far the most frequent cancer among women, with an estimated 1.38 million new 
cases diagnosed in 2008 (23% of all cancers in women). Australia, Europe, and North 
America are the high-risk areas, where 6% of women are estimated to develop invasive breast 
cancer before the age of 75 (Tavassoli et al. 2003). However, the prognosis has improved, and 
89% of the patients in Finland are still alive 5 years after diagnosis (www.cancer.org, 
www.cancer.fi). The exact etiology of breast cancer is unknown. However, reasons for breast 
cancer development are multifactorial, involving reproductive factors and hormones, as well 
as lifestyle and diet (Tavassoli et al. 2003). Known predisposing and protective factors 
against breast cancer are summarized in Table 1.  
 
 
Table 1. Predisposing and protective factors against breast cancer. 
Female breast cancer 
Predisposing factors Protective factors 
Family history of breast cancer 
Benign breast disease 
Exposure to ionizing radiation 
Early menarche 
Late menopause 
Childlessness 
Oral contraceptives 
Abundant alcohol consumption 
Postmenopausal obesity 
Rapid growth and greater adult height 
Low physical activity 
Early age at full-term pregnancy 
Breast-feeding 
Vitamin D 
High intake of fresh fruits and vegetables 
High intake of fiber 
 
 
Transforming genetic and epigenetic events in a single cell initiate breast carcinogenesis. 
Progression of the disease results from additional accumulation of mutations combined with 
clonal growth and selection of the cells, leading to heterogeneous disease with a broad variety 
of pathological appearance and diverse clinical outcomes (Simpson et al. 2005). To be able to 
Introduction to the subject 
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treat patients appropriately, ways to identify the disease are necessary. The World Health 
Organization classifies breast epithelial tumors into 19 subgroups based on their histological 
appearance. Factors both prognostic and predictive, like tumor-node metastasis (TNM) stage, 
and expression of hormonal and growth factor receptors provide information on how to treat 
patients and predict disease progression. Recently, gene expression arrays have been 
introduced as a model to study breast cancer biology, improve diagnosis, identify prognostic 
signatures, predict cancer response to adjuvant therapy, and identify therapeutic targets 
(Cheang et al. 2008). These prognostic and predictive factors or gene expression profiling 
methods are, however, not comprehensive, and new markers and methods to predict disease 
development are vital.  
 
Review of the Literature 
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REVIEW OF THE LITERATURE 
 
1. POSTTRANSCRIPTIONAL GENE REGULATION 
 
Regulation of eukaryotic gene expression is a tightly controlled process that can occur at 
multiple levels consisting of transcription, RNA processing, mRNA transport, turnover, 
storage, and translation. Transcription is the best-known regulatory method of eukaryotic 
gene expression, but the role of posttranscriptional regulation is emerging. Two main classes 
of RNA-binding factors, RNA-binding proteins (RBPs) and small noncoding RNAs, i.e. 
microRNAs (miRNAs), and short interfering RNAs, control the posttranscriptional gene 
regulation. 
 
In vertebrates, the stability of mRNA can range from less than an hour to over 12 hours 
(Sharova et al. 2009), leading to a great difference in the abundance of transcripts. The half-
lives of mRNAs are dependent on cis-acting elements in the mRNA and trans-acting factors 
recognizing these elements. The association of RBPs and miRNAs determines the fate of the 
mRNA and their recruitment to different sites in the cell, like processing bodies (P-bodies), 
stress-granules, polysomes, exosomes, and RNA-induced silencing complex (RISC), each 
specialized in distinct aspects of mRNA metabolism (Figure 2). One such cis-acting element 
in the mRNA is a turnover and translation regulatory element that trans-acting RBPs 
recognize. 
 
 
1.1 Turnover and translation regulatory RNA-binding proteins (TTR-RBPs) 
 
TTR-RBPs recognize and bind to specific cis-acting elements in mRNA sequences frequently 
located in the 5’ and the 3’ untranslated regions (UTR), causing alterations in mRNA stability 
or translation efficiency or both (Pullmann et al. 2007). Conventionally, these elements in the 
mRNAs have been called AU-rich elements (AREs), since the first stability elements found 
were enriched with adenylate and uridylate (AU) or uridylate (U) stretches (Brennan et al. 
2001). TTR-RBPs are a heterogeneous group of proteins with tightly connected functions, and 
their influence on the same target mRNA may be competitive or cooperative (Table 2). 
Tristetraproline (TTP), AU-binding factor 1 (AUF1, also called hnRNP D), the K homology 
splicing regulatory protein (KSRP), nuclear factor 90 (NF90), human antigen R (HuR), T-
cell-restricted intracellular antigen 1 (TIA-1), and TIA-1-related protein (TIAR) can all 
associate with its cognate mRNA and with other TTR-RBPs mRNAs and regulate their 
expression (Tchen et al. 2004, Pullmann et al. 2007). TTP, AUF1, KSRP, and butyrate 
response factor 1 (BRF1) have all been primarily associated with mRNA decay. Human 
antigen (Hu) proteins (HuR, HuB, HuC, HuD) and NF90 can promote mRNA stability or 
affect translation of their target transcripts or both. TIA-1 and TIAR have been shown to 
inhibit translation. Additionally, nucleolin, αCP1, RNPC1, CUG-BP2, and PAIP2 have also 
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been suggested to promote stability of their target transcripts and CUG-BP1 to enhance 
translation. Their functions are, however, not well characterized (Abdelmohsen et al. 2008a).  
 
 
Table 2. TTR-RBPs regulate the same target genes, and their effect on mRNA may be 
competitive or cooperative. 
 
TTR-RBP Target mRNAs* Effect on mRNA 
TTP GM-CSF, c-fos, TNF-α, COX-2, IL-2, VEGF, IL-8, 
interferon-γ, TTP 
 
mRNA decay 
AUF1 Cyclin D1, c-fos, GM-CSF, TNF-α, IL-1β, IL-3, 
p16, p21, COX-2  
 
c-Myc 
 
mRNA decay 
 
 
Increase in translation 
KSRP c-fos, c-jun, iNOS, TNF-α, IL-2 
 
mRNA decay 
BRF1 TNF-α, IL-3 
 
mRNA decay 
NF90 MKP-1, VEGF, IL-2, p21, MyoD 
 
mRNA stabilization 
TIA-1 COX-2, TNF-α, CASP8, cytochrome c 
 
Decrease in translation 
TIAR COX-2, c-myc, EIF4A, EIF4E, MMP-13 
 
Decrease in translation 
HuR c-fos, p21, cyclins A2/B1/E1/D1, iNOS, GM-CSF, 
VEGF, SIRT1, TNF-α, Bcl-2, Mcl-1, COX-2, uPA, 
uPAR, IL-3, MKP-1, p53, HIF-1α, Mdm-2, Snail, 
MMP-9, eIF4E 
 
p53, ProTα, cytochrome c, MKP-1, cyclin A2, Bcl-2, 
VEGF, TSP-1 
 
p27, IGF-IR, Wnt5a, TNF-α, c-Myc 
mRNA stabilization 
 
 
 
 
Increase in translation 
 
 
Decrease in translation 
 
* References: TTP (Sully et al. 2004, Tchen et al. 2004, Ogilvie et al. 2005, 2009, Hau et al. 2007, 
Suswam et al. 2008), AUF1 (Cok et al. 2004, Lal et al. 2004, Wang et al. 2005, Liao et al. 2007, 
Abdelmohsen et al. 2008a, Chang et al. 2010), KSRP (Linker et al. 2005, Abdelmohsen et al. 2008a), 
BRF1 (Stoecklin et al. 2002, Abdelmohsen et al. 2008a), NF90 (Shim et al. 2002, Shi et al. 2005, 
Abdelmohsen et al. 2008a, Kuwano et al. 2008b), TIA-1 (Piecyk et al. 2000, Lopez de Silanes et al. 
2005, Kawai et al. 2006), TIAR (Yu et al. 2003, Mazan-Mamczarz et al. 2006, Liao et al. 2007, 
Abdelmohsen et al. 2008a), HuR (Levy et al. 1998, Wang et al. 2000a, 2000b, Dean et al. 2001, Ming 
et al. 2001, Kullmann et al. 2002, Akool et al. 2003, Mazan-Mamczarz et al. 2003, 2008a, Sengupta et 
al. 2003, Tran et al. 2003, Lal et al. 2004, 2005, Winzen et al. 2004, Linker et al. 2005, Meng et al. 
2005, Guo et al. 2006, Kawai et al. 2006, Leandersson et al. 2006, Abdelmohsen et al. 2007a, 2007b, 
Dong et al. 2007, Galban et al. 2008, Kuwano et al. 2008b, Ghosh et al. 2009, Kim et al. 2009, 
Topisirovic et al. 2009, Doller et al. 2010, Kakuguchi et al. 2010, Kurosu et al. 2011). 
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Figure 2. Posttranscriptional regulation of RNA. After transcription, premature mRNA is 
processed to mature mRNA, and transported to the cytoplasm, where RBPs and miRNAs 
participate in the regulation of mRNA translation, degradation, and storage. 
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2. HUMAN ANTIGEN R, HUR 
 
HuR (HuA) is a member of the embryonic lethal abnormal vision (ELAV)-like / Hu-protein 
family of RBPs. This protein family consists of ubiquitously expressed HuR protein and three 
other family members, HuB/HelN1, HuC, and HuD, that are mainly expressed in the neuronal 
tissues. The Elav gene was first discovered in Drosophila, where it regulates the development 
and maintenance of the nervous system. Human HuR was first cloned and characterized by 
Ma et al. in 1996. HuR is localized to human chromosome 19p13.2, and the protein consists 
of 326 amino acids having a molecular mass of 36 kD. HuR shares over 90% amino acid 
similarity with its other family members (Ma et al. 1996, 1997).  
 
HuR consists of three RNA recognition motifs (RRM) and a hinge region where the HuR 
nucleocytoplasmic shuttling (HNS) sequence is located (Figure 3). Through RRM1 and 
RRM2, HuR binds to and mediates recognition of its target transcripts. RRM3 is thought to 
bind the poly(A) tail and maintain stability of the RNA-protein complex (Brennan et al. 2001, 
Hinman et al. 2008). Like other TTR-RBP, HuR recognizes elements rich in AU or U (AREs) 
usually located in the 5’ and/or 3’-UTR of its target transcripts, mediating their stabilization 
or translation or both (Brennan et al. 2001, Lopez de Silanes et al. 2004). The exact 
mechanisms by which HuR stabilizes or regulates translation of target mRNAs are not 
completely understood. However, HuR probably competes with other RBPs, and the net 
effect of the RBPs then resolve if the mRNA is stabilized or degraded (Abdelmohsen et al. 
2010a). The translational control of HuR has been proposed to cause its effect through 
internal ribosomal entry sites (IRES) in the 5’UTRs of its targets (Kullmann et al. 2002), or to 
compete or cooperate with miRNAs (Bhattacharyya et al. 2006, Kim et al. 2009). However, 
stability- and translation-independent roles of HuR have also been suggested, i.e. functioning 
as a splicing factor and apoptosis inducer (Izquierdo 2008, Mazroui et al. 2008, von Roretz et 
al. 2010). Through its target transcripts, HuR participates in diverse biological processes in 
the cell like transformation, immune response, cell survival, inflammation, cell cycle control, 
differentiation, and senescence (Abdelmohsen et al. 2007a, 2008a, 2010a, Masuda et al. 
2009). The chromosomal locus of HuR is associated with a number of translocations and 
oncogenic gains in human tumors (Ma et al. 1997). However, primarily alterations in HuR 
function depend neither on protein abundance, nor on mutations of the gene, nor on 
alterations in its copy number, but on subcellular localization of HuR and the binding of HuR 
to its target transcripts. 
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Figure 3. Schematic of HuR protein with posttranslational modification information. HuR 
consists of three RNA recognition motifs (RRM) and a hinge region (amino acids 186-224) 
containing the HuR nucleocytoplasmic shuttling sequence (HNS). Modified from the article 
by Abdelmohsen et al. 2010a. References: 1. Abdelmohsen et al. 2007, 2. Lafarga et al. 2009, 
3. Doller et al. 2007, 4. Abdelmohsen et al. 2009, 5. Kim et al. 2008, 6. Li et al. 2002, 7. 
Doller et al. 2008, 8. Mazroui et al. 2008, 9. Kim et al. 2008. 
 
 
2.1 Nucleocytoplasmic shuttling of HuR 
 
Although HuR is predominantly nuclear, its role in the nucleus has remained rather indistinct. 
HuR is associated with mRNA splicing and plays a role in polyadenylation and export of its 
target transcripts from the nucleus (Izquierdo 2008, Papadopoulou et al. 2010). However, the 
cytoplasmic localization of HuR has been associated with its ability to stabilize or mediate 
translation of its target transcripts, and thus in the cell it participates in diverse biological 
processes. Nucleocytoplasmic translocation of HuR can occur by at least two independent 
mechanisms and is influenced by kinases: cyclin-dependent kinase 1 (Cdk1, G2-phase kinase 
also known as cell division cycle 2), AMP-activated protein kinase (AMPK), protein kinase C 
(PKC), and mitogen-activated protein kinase (MAPK) p38 that again react with various 
endogenous and external stimuli such as hormones, cytokines, growth factors, UV radiation, 
hypoxia, lack of nutrients, and oxidative stress (Doller et al. 2008b).  
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HNS is located between RRM2 and -3, and contains a bidirectional shuttling signal that 
enables nuclear export and importation of HuR (Figure 3). Transport receptors transportin-1 
and -2 and importin-1α recognize the HNS and mediate the translocation of HuR across the 
nuclear membrane through nuclear pore complexes (Gallouzi et al. 2001b, Rebane et al. 
2004, Wang et al. 2004). Adapter proteins pp32 and acidic protein rich in leucine also bind 
HuR and mediate its transportation via the nuclear export receptor chromosome maintenance 
region 1 (Gallouzi et al. 2001a). What determines the HuR shuttling pathway is unknown, but 
most likely HuR, its target transcript, and an activating signal all play a role. 
 
 
2.2 Signaling pathways related to HuR regulation 
 
Cytoplasmic shuttling of HuR is modulated by cellular signaling cascades including MAPK 
and its downstream kinase MK2, AMPK, and the PKC family. Additionally, Cdk1 has been 
connected with UVC-triggered HuR shuttling (Doller et al. 2008b).  
 
AMPK is an essential regulator of cell metabolism. It is activated by the increase in the 
AMP/ATP-ratio caused for example by lack of nutrients or by physical exercise. Activation of 
AMPK leads to the inhibition of energy-conserving pathways and the activation of catabolic 
pathways that produce ATP. AMPK does not phosphorylate HuR directly, but activated 
AMPK phosphorylates (S105) and acetylates (K22) importin-α1, a nuclear transportation 
protein, leading to the nuclear accumulation of HuR (Figure 4) (Wang et al. 2004). 
 
Ataxia telangiectasia-mutated (ATM) and ATM and Rad3-related (ATR) kinases detect DNA 
damage. ATM is mainly activated by double-strand breaks in DNA caused by IR, whereas 
ATR can be activated by damaging agents such as UV and chemical inhibitors of DNA 
replication (Yang et al. 2004, Kim et al. 2010). ATM/ATR phosphorylates checkpoint kinase 
(Chk) 1, which further leads to phosphorylation of Cdk1 and inactivation of this kinase (Kim 
et al. 2010). Silencing of Cdk1 increases cytoplasmic levels of HuR and its interaction with 
its target transcripts. For contrast, Cdk1 can phosphorylate HuR at position serine (S) 202 
during the G2/M phase and promote the nuclear localization of HuR (Figure 4) (Kim et al. 
2008a). 
 
MAPKs are serine/threonine-specific protein kinases activated by several extracellular 
signals, thus leading to various cellular activities such as gene expression, mitosis, 
differentiation, proliferation, and cell survival and apoptosis (Figure 4) (Keshet et al. 2010). 
MAPKs increase cytoplasmic localization of HuR and so participate in stabilization or 
translation or both of tumor necrosis factor α (TNF-α), interleukine (IL) 6 and IL-8, 
cyclooxygenase 2 (COX-2), c-fos, granulocyte macrophage colony-stimulating factor (GM-
CSF), urokinase (uPA), and urokinase receptor (uPAR) (Doller et al. 2008b). Interestingly, 
HuR also stabilizes and facilitates translation of MAPK phosphatase-1, MKP-1 (Kuwano et 
al. 2008a), a protein that dephosphorylates and inactivates MAPKs extracellular-signal 
regulated kinase, c-Jun N-terminal kinase (JNK), and p38. A negative feedback loop has been 
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suggested in which a stress signal activates MAPKs, leading to activation of transcription 
factors that increase activity of stress-response genes. In this model, MAPK-activated HuR 
stabilizes and enhances translation of stress-response mRNAs, including MKP-1, which 
production eventually leads to shut-off of MAPKs. 
 
 
 
 
 
 
Figure 4. Signaling pathways related to HuR regulation. 
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PKCα and PKCδ are members of a PKC family of serine/threonine protein kinases consisting 
of at least 10 different isoforms (Doller et al. 2008b). PKCs are related to several biological 
processes including development, differentiation, proliferation, and carcinogenesis, and 
respond to a variety of signals including hormones and peptides such as Angiotensin II 
(AngII), epidermal growth factor (EGF), and ATP (Doller et al. 2007, 2008a). PKCα can 
phosphorylate HuR at the sites of S158 and S221, and PKCδ at the sites of S221 and S318 
(Doller et al. 2007, 2008a, 2010). PKCα- or PKCδ-mediated serine-phosphorylation of HuR 
leads to nucleocytoplasmic shuttling of HuR, and to increased stabilization of its target 
transcripts (e. g. COX-2, cyclin D1 and cyclin A; Figure 4).  
 
Additionally, a still-unidentified kinase can phosphorylate HuR at the site of S242, which 
prevents its cytoplasmic localization and posttranscriptional regulation of cyclin A2 and B1 
(Kim et al. 2008b). 
 
2.3 MicroRNAs regulating HuR expression 
 
MicroRNAs (miRNAs/miR) are short ∼22 nucleotide long non-coding RNA molecules that 
participate in mRNA regulation by activating an endonuclease cleavage, inhibiting translation 
or enhancing mRNA decapping. MiRNAs regulate several biological processes such as 
development, cell differentiation, the cell division cycle, and apoptosis, as well as cancer 
(Garzon et al. 2009). They are generated from a stem-loop structure forming precursor 
transcripts that are transported to the cytoplasm and cleaved by Dicer, an endoribonuclease in 
the RNase III family. Matured miRNAs accumulate in the RISC and function primarily as 
repressors of mRNA stability or translation or both (Valencia-Sanchez et al. 2006). Thus far, 
four miRNAs have been shown to repress HuR expression in cells (Table 3). MiR-16, miR-
125a, and miR-519 inhibit translation of HuR, while miR-34 inhibits both stability and 
translation of HuR expression (Abdelmohsen et al. 2008b, 2010b, Guo et al. 2009, Kojima et 
al. 2010, Xu et al. 2010). MiR-519 represses HuR translation without affecting HuR mRNA 
abundance, resulting in reduced proliferation of the cells (Abdelmohsen et al. 2008b). In 
comparison to cancers and adjacent tissues of lung, ovary, and kidney specimens, cancers 
show markedly higher levels of HuR expression and lower miR-519 levels than do their 
healthy tissue controls (Abdelmohsen et al. 2010b). MiR-16 and -125a inhibit HuR translation 
in breast cancer cells, and similar to miR-519, miR-16 is inhibited in breast cancer specimens 
(Xu et al. 2010). Re-establishment of miR-125a in breast cancer cells inhibits cell growth by 
restraining proliferation and inducing apoptosis (Guo et al. 2009). MiR-34a inhibition of HuR 
expression leads to repression of its downstream targets sirtuin 1 (SIRT1) and B-cell 
lymphoma 2 (Bcl-2) in prostate cancer cells. Inhibition of miR-34a expression, in contrast, 
leads to paclitaxel resistance via up-regulation of SIRT1 and Bcl-2 in the prostate cells 
(Kojima et al. 2010). These results thus show that miRNAs are important regulators of HuR 
expression and may prove to be functional in cancer treatments as tumor repressors. 
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Table 3. MicroRNAs in HuR regulation. 
miRNA miRNA 
expression in 
cancers 
miRNA effect on 
HuR 
Experimental data * 
miR-16 Inhibited in breast 
tumors 
Inhibit translation miR-16 inhibits HuR expression 
leading to inhibition of COX-2, c-
fos, and SIRT1. 
miR-34a Inhibited in several 
cancers, e.g. breast 
Inhibit mRNA 
stability and 
translation 
miR-34a inhibits HuR expression 
leading to inhibition of Bcl-2 and 
SIRT1. 
miR-125a Inhibited in breast 
cancer 
Inhibit translation miR-125a inhibits HuR 
expression and suppresses cell 
growth by inducing apoptosis and 
reducing cell migration. 
miR-519 Reduced 
expression in lung, 
kidney and ovarian 
cancers 
Inhibit translation miR-519 alters cell proliferation 
by regulating HuR protein 
abundance. 
 
* References: Iorio et al. 2005, Abdelmohsen et al. 2008b, 2010b, Guo et al. 2009, Kojima et al. 2010, 
Xu et al. 2010, Vogt et al. 2011. 
 
 
2.4 Binding of HuR to its target transcripts 
 
HuR undergoes modifications that alter its binding to its target transcripts (Figure 3). HuR can 
be phosphorylated (Abdelmohsen et al. 2007b, Doller et al. 2007, 2008a), methylated (Li et 
al. 2002), cleaved (Mazroui et al. 2008) and ubiquitinylated (Abdelmohsen et al. 2009). 
Additionally, HuR mRNA contains multiple polyadenylation sites (Al-Ahmadi et al. 2009).  
 
Eight recently discovered phosphorylation sites in the HuR protein sequence affect the 
binding affinity of HuR to its target transcripts or subcellular localization of HuR or both 
(Figures 3 and 4). HuR can be phosphorylated at the sites of S88, S100, S158, S202, S221, 
S242, S318, and threonine (T) 118. Kinases mediating these phosphorylations are Chk2, p38 
MAPK, PKC, and Cdk1 (Abdelmohsen et al. 2007b, Doller et al. 2007, 2008a, Lafarga et al. 
2009). In oxidative stress, Chk2 phosphorylates HuR on sites S88, S100, and T118, causing 
HuR to dissociate from its target mRNA SIRT1, which leads to degradation of SIRT1 mRNA, 
lowering of the protein abundance, and finally to reduced in cell survival (Abdelmohsen et al. 
2007b). Similarly, phosphorylation of HuR at the site of T118 by p38 MAPK improves 
binding of HuR to p21Cip1, leading to an effective G1 arrest of the cells (Lafarga et al. 2009). 
Phosphorylation of HuR by PKCα at the sites of S158 and S221 enhances HuR binding to 
COX-2 mRNA, and PKCδ phosphorylation at the sites of S221 and S318 causes enhanced 
binding of HuR to COX-2, cyclin A, and D1 mRNAs in the cells (Doller et al. 2007, 2010). 
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Methylation of HuR at the site of R217 and to a lesser extent at the site of R206 (both located 
in the hinge region) is mediated by coactivator-associated arginine methyltransferase 1, 
CARM1 (Figure 3) (Li et al. 2002). The exact meaning of HuR methylation is still unclear, 
but results from differentiating rat liver cells suggest that HuR methylation causes target 
transcript destabilization or inhibition of its translation or both (Vazquez-Chantada et al. 
2010). Ubiquitination of HuR at the site of K182 reduces HuR protein abundance, leading to a 
decrease in HuR target mRNAs related to cell proliferation, and to enhancement of cell 
survival by allowing cells to repair heat-damaged components (Abdelmohsen et al. 2009). As 
a response to lethal stress, HuR is transported to the cytoplasm with pp32/PHAP-I, after 
which caspase-3 and -7 cleavage HuR at the site of D226, producing fragments of 24 kD and 
9 kD. This cleavage of HuR promotes cell death (Mazroui et al. 2008). 
 
HuR mRNA 3’UTR consists of multiple polyadenylation sites (1.5-, 2.7-, 6-kb) that produce 
alternative variants with differing stability elements. The long 6-kb HuR mRNA contains a 
typical class I ARE sequence (AUUUA) and is more labile than the 1.5- and 2.7-kb 3’UTR 
isoforms lacking the classical ARE and having ATTAAA and U-rich stretches in their 
sequences (Al-Ahmadi et al. 2009). HuR binds to and regulates its own mRNA, but other 
TTR-RBPs like AUF1, TTP, NF90, TIA-1, and TIAR also bind HuR. These variants respond 
differently to HuR-mediated stabilization, when differences in the stability elements cause 
divergence in the abundance of HuR transcripts in the cells (Al-Ahmadi et al. 2009). This can 
have an effect on tissue-specific expression, mRNA localization, mRNA decay, and 
translation.  
 
 
3. HUR IN CARCINOGENESIS 
 
HuR has been associated with diverse roles in the cells including differentiation, cell response 
to damaging stimuli, and immune and inflammatory responses, as well as carcinogenesis. 
HuR can mediate functions considered hallmarks of cancer (Hanahan et al. 2011), i.e. 
promote the expression of proteins that increase proliferation, enhance cell survival, reduce 
apoptosis, improve angiogenesis, reduce immune recognition, and facilitate invasion and 
metastasis (Figure 5).  
 
 
3.1 HuR regulates mRNAs encoding proteins involved in cancer development  
 
A cancer cell must gain the ability to promote proliferation in order to grow into a tumor 
mass. HuR enhances the stability and raises the levels of many cyclins, which activate cyclin-
dependent kinases at different cell cycle phases, and cause cell division to shorten and tumor 
mass to increase. HuR promotes the expression of cyclin D1, cyclin E1, cyclin A2, cyclin B1, 
EGF and eukaryotic translation initiation factor (Wang et al. 2000a, Lal et al. 2004, Sheflin et 
al. 2004, Guo et al. 2006, Topisirovic et al. 2009, Kakuguchi et al. 2010). Additionally, HuR 
can inhibit translation of p27, a factor that controls Cdk2 and prevents cell cycle transition to 
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the S phase (Kullmann et al. 2002). 
 
To be able to survive, tumor cells must defeat death-causing signals. HuR promotes 
expression of many anti-apoptotic proteins (Prothymosin-α (Pro-Tα), Bcl-2, myeloid cell 
leukemia sequence 1 (Mcl-1), SIRT1, p21, Mdm2) and represses the production of a pro-
apoptotic protein (c-Myc), thus having an anti-apoptotic effect on cancer cells (Wang et al. 
2000b, Lal et al. 2005, Abdelmohsen et al. 2007a, 2007b, Ghosh et al. 2009, Kim et al. 
2009). Furthermore, HuR promotes exon 6 skipping on Fas mRNA by binding to an exon-
splicing silencer. Exclusion of exon 6 by an alternative RNA splicing of the primary transcript 
of the apoptosis receptor Fas produces a soluble isoform that prevents apoptosis (Izquierdo 
2008, 2010). What is important to notice, however, is that under prolonged and lethal cell 
stress, HuR is translocated to the cytoplasm together with apoptosome activator pp32/PHAP-
I, and goes through cleavage that accelerates the progress of apoptosis (Mazroui et al. 2008). 
Although HuR facilitates translation of p53 (Mazan-Mamczarz et al. 2003), a powerful pro-
apoptotic protein, HuR has a strong anti-apoptotic effect on cancer cells via its other targets, 
leading to greater survival of cancer cells. 
 
When a tumor grows, cancer cells need to extend the local vasculature to protect delivery of 
nutrients and oxygen. HuR has been shown to affect the expression of pro-angiogenic factors 
like hypoxia-inducible factor 1α (HIF-1α), vascular endothelial growth factor (VEGF), and 
COX-2, leading to an increase in tumor vasculature (Levy et al. 1998, Sheflin et al. 2004, 
Galban et al. 2008, Kurosu et al. 2011). HuR enhances the expression of HIF-1α and VEGF 
that are strongly expressed at low oxygen concentrations, and increases the stability and 
translation of COX-2 mRNA (Dixon et al. 2001, Nabors et al. 2001), a key enzyme in the 
formation of prostanoids. COX-2 is highly expressed in many cancers favoring cancer 
development by inhibiting apoptosis, and promoting cell proliferation, and angiogenesis 
(Sahin et al. 2009, Ghosh et al. 2010). HuR can also enhance the expression of tumor 
suppressor and angiogenesis inhibitor TSP1. However, when MCF7 breast cancer cells 
overexpress the MCT-1 (multiple copies in T cell lymphoma 1) oncogene, the association of 
HuR with TSP1 mRNA is diminished (Mazan-Mamczarz et al. 2008a), suggesting a dual role 
for HuR: When cancer develops, the association of HuR with its target mRNAs alters, 
favoring cancer development. 
 
Immune system scrutiny leads to elimination of harmful material from the body such as tumor 
cells, so tumor cells must create some mechanism to avoid recognition by the immune cells. 
HuR raises MKP-1 levels in immune cells by promoting translation, thus causing suppression 
of immune function (Barbisan et al. 2009, Lim et al. 2009). Transforming growth factor β 
(TGF-β) can suppress the development of early-stage tumors, but it promotes proliferation, 
invasiveness, and metastasis in late-stage tumors (Watnick et al. 2003, Stoppoloni et al. 
2008). Some studies have linked the tumorigenic effect of TGF-β to the fact that it enables 
tumor cells to evade immune recognition (Zabrenetzky et al. 1994, Keyse 2008). HuR binds 
and regulates TGF-β expression post-transcriptionally in malignant brain tumors (Nabors et 
al. 2001). Additionally COX-2, a target for HuR regulation, can modify the immunological 
response by altering the expression of the immunoactive cytokines which aid tumor cells in 
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escaping immune system elimination (Ghosh et al. 2010). 
 
To be able to invade adjacent tissue or metastasize to distant tissues, tumor cells need to 
acquire the ability to change their interaction with their local environment. HuR can enhance 
cell motility by improving the expression of proteins related to degradation of extracellular 
matrix (matrix metalloproteinase 9 (MMP-9), uPA, and uPAR) and by enhancing the 
expression of Snail, a protein related to epithelial-to-mesenchymal transition, EMT (Akool et 
al. 2003, Huwiler et al. 2003, Tran et al. 2003, Dong et al. 2007). 
 
 
 
 
Figure 5. HuR participates in cancer development via regulation of its target transcripts.  
 
 
3.2 HuR expression in cancer 
 
The first hint of the role of Hu proteins in cancer was reported in small cell lung cancer where 
a higher titer of anti-Hu antibody was associated with a paraneoplastic syndrome (Dalmau et 
al. 1990). One of the first human cancer tissue studies was performed by Nabors et al. (2001), 
who showed that tumors of the central nervous system express HuR. All brain tumor tissues 
studied expressed HuR; the strong nuclear HuR protein expression was, however, limited to 
high-grade malignancies (glioblastoma multiforme and medulloblastoma). The importance of 
cytoplasmic HuR expression in cancer biology was first indicated in mice where chemically 
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induced lung tumors showed elevated cytoplasmic HuR expression (Blaxall et al. 2000). 
Today, the role of HuR in cancer development and its association with clinicopathological 
parameters have been studied with cell lines and clinical cancer specimens in several cancers. 
Importantly, HuR mRNA levels do not change noticeably between normal and cancer tissue 
(Brennan et al. 2009, Guo et al. 2009), but the intracellular localization of HuR protein seems 
important. 
 
In colon carcinoma, the subcellular location of HuR within the tumor cells varies from that in 
normal colon cells (Lopez de Silanes et al. 2003, Young et al. 2009). The relative cytoplasmic 
abundance of HuR is lowest in the normal mucosa, moderately higher in adenomas, and 
highest in carcinomas. In normal mucosa, HuR expression is strongest at the base of the crypt 
and decreases towards the top of the crypt. HuR expression associates strongly with cellular 
proliferation (Lopez de Silanes et al. 2003). This suggests a possible role for HuR in colon 
carcinogenesis to upregulate the expression of proliferative cells. In nude mice, colon 
carcinoma cells that overexpress HuR develop larger tumors (Lopez de Silanes et al. 2003). 
Conversely, HuR inhibition with siRNAs reduces the growth of tumors in nude mice (Lopez 
de Silanes et al. 2003).  
 
Cytoplasmic HuR positivity has been found in 53% of colorectal adenocarcinoma cases and 
the expression of cytoplasmic HuR associated with increased COX-2 expression as well as 
high tumor stage (Denkert et al. 2006). A large tissue microarray analysis of colorectal 
adenocarcinoma cases showed that along with overall TNM stage, high total HuR expression 
within the tumors was an independent marker for poor prognosis (Yoo et al. 2009). Neither 
cytoplasmic nor nuclear expression of HuR showed statistically significant impact on overall 
survival. However, patients with a high nuclear-to-cytoplasmic ratio of HuR expression show 
improved survival (Yoo et al. 2009). Cytoplasmic HuR expression has been studied also in 
normal colorectal mucosa, adenomas, adenocarcinomas from familial adenomatous polyposis 
patients, and sporadic colorectal carcinoma. Cytoplasmic HuR expression was increased in 
familial adenomatous polyposis adenocarcinomas and sporadic carcinomas, and also here was 
associated with elevated COX-2 expression (Brosens et al. 2007).  
 
In gastric adenocarcinoma, cytoplasmic HuR expression associates with high COX-2 
expression and with reduced survival from the disease, whereas nuclear HuR positivity does 
not (Mrena et al. 2005). HuR expression has been aberrantly elevated in gastric tumors when 
compared to nontumorigenic tissue. Additionally, nuclear factor κB enhances HuR 
transcription and PI3K/AKT signaling to activate HuR and lead to progression of human 
gastric cancer (Kang et al. 2008). 
 
In ovarian carcinomas, nuclear as well as cytoplasmic HuR expression is significantly higher 
than in borderline tumors (tumors of low malignant potential) or in healthy ovaries. 
Cytoplasmic HuR expression associates significantly with increased COX-2 expression, high 
histologic grade, and mitotic activity. Cytoplasmic HuR expression is an independent marker 
of reduced survival in ovarian cancers (Denkert et al. 2004a). In serous type ovarian cancer, 
cytoplasmic HuR expression associates with high COX-2 expression, high tumor grade, and 
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reduced survival (Erkinheimo et al. 2003); in mucinous ovarian carcinoma, cytoplasmic HuR 
expression correlates with increased COX-2 expression (Erkinheimo et al. 2005). 
Additionally, cytoplasmic HuR expression in ovarian cancer has been associated with reduced 
survival and elevated β-tubulin levels (Raspaglio et al. 2010). Interestingly, in one study (Yi 
et al. 2009), nuclear HuR expression associates with the invasive type of the cancer, with high 
grade, large residual disease, and poor disease-free survival. Nuclear HuR expression is an 
independent prognostic factor of poor survival. These data indicate that nuclear HuR also may 
play a role in ovarian carcinogenesis, but the function of HuR in the nucleus needs further 
clarification. 
 
In normal prostate tissue, HuR expression is predominantly nuclear, while in the cancer cases 
the cytoplasmic HuR expression is elevated (Niesporek et al. 2008). Similarly, in another 
study involving clinical specimens from normal-looking prostate epithelium, prostate tissue 
with atrophy, high-grade prostatic epithelium, and prostate carcinoma, the cytoplasmic HuR 
expression increased towards a more malignant phenotype (Barbisan et al. 2009). 
Cytoplasmic expression of HuR is elevated in prostate cancer and this is linked to altered 
expression of COX-2 as well as to adverse patient prognosis, suggesting that cytoplasmic 
HuR expression associates with prostate carcinogenesis and development (Niesporek et al. 
2008, Barbisan et al. 2009). 
 
Interestingly, in pancreatic cancer cases, high cytoplasmic HuR expression is found to be 
beneficial for patients: HuR overexpression has sensitized pancreatic cancer cells to 
gemcitabine at least in part by associating with dCK mRNA, a deoxy-cytidine kinase that 
metabolizes and activates gemcitabine in the cells. In pancreatic adenocarcinoma patients 
treated with adjuvant gemcitabine-based radiochemotherapy or chemotherapy, those patients 
with low cytoplasmic HuR expression had a seven-fold greater mortality than did patients 
with high cytoplasmic HuR expression (Costantino et al. 2009). HuR seems to be a key 
mediator of gemcitabine efficacy by regulating dCK abundance in pancreatic cancer cells. 
However, in the absence of a comparable group of patients receiving no gemcitabine, the 
predictive value of HuR cannot be truly evaluated (Costantino et al. 2009, Marechal et al. 
2009). Recently, patients with high cytoplasmic HuR expression showed better overall 
survival than did patients with low cytoplasmic HuR expression; however, in the same 
patients, high cytoplasmic HuR expression associated with high tumor T-stage (Richards et 
al. 2010). Increased HuR levels and activity may facilitate a more efficient drug response, but 
conversely, increased HuR levels may also promote tumor cell survival by facilitating protein 
synthesis or stabilizing mRNAs beneficial for cancer development or both.  
 
HuR expression has also been studied in Merkel cell carcinoma (MCC), a rare neuroendocrine 
carcinoma of the skin. There, primary MCCs and their lymph node metastasis express 
cytoplasmic HuR, while in contrast the non-neoplastic skin does not (Koljonen et al. 2008). 
Cytoplasmic expression of HuR may contribute to the carcinogenesis of MCC. Ewing 
sarcoma is a malignant round-cell tumor, and these cancer cells are found in bone or in soft 
tissue, most often in the pelvis, femur, humerus, and ribs. In Ewing sarcoma, 17% of the cases 
showed nuclear HuR positivity, but no cytoplasmic HuR expression was detectable (Do et al. 
Review of the Literature 
 27 
2008). In mesothelioma, a cancer primarily caused by exposure to asbestos, overall survival is 
significantly shortened in patients who express cytoplasmic HuR (Stoppoloni et al. 2008), and 
in renal cell carcinoma (RCC), cytoplasmic HuR expression associates with tumor stage, and 
reduced survival (Ronkainen et al. 2010). That HuR regulates COX-2 expression in RCC 
cells may be a plausible mechanism of the HuR-mediated aggressive behavior of RCC. HuR 
is expressed in a variety of cancers, showing an association with reduced survival, which 
suggests that HuR plays a role in the development of several cancers. 
 
 
3.3 HuR in mice 
 
In vitro HuR regulates genes involved in cellular processes such as tumorigenesis, cell cycle 
control, inflammation, cell stress response, and apoptosis (Brennan et al. 2001, Dixon et al. 
2001, Gorospe 2003, Sengupta et al. 2003, Abdelmohsen et al. 2007a). The role of HuR in 
vivo is, however, still quite unclear. HuR expression can already be detected at embryonic day 
(E) 8.5, and from then on it is expressed at every stage of embryonic development, and up to 
adulthood (Gouble et al. 2000). Overexpression of HuR in transgenic mice leads to a defect in 
male gamete functioning, and this suggests a role for HuR in spermatogenesis (Levadoux-
Martin et al. 2003). Heterozygous Elavl1+/- mice appear phenotypically normal and are able 
to reproduce (Ghosh et al. 2009, Katsanou et al. 2009), but Elavl1-/- mice die in utero. This 
embryonic lethality is due to their defects in extraembryonic placental development, meaning 
that HuR expression is required for labyrinth branching morphogenesis (Katsanou et al. 
2009). The epiblast-specific deletion of HuR also leads to an embryonic lethality, at the latest 
on E19.5. Embryos have major defects in skeletal and spleen development, and 
dysmorphologies in the lungs (Katsanou et al. 2009), suggesting a multifaceted role for HuR 
during embryonic development. Postnatal global deletion of HuR causes atrophy of 
hematopoietic organs, extensive loss of intestinal villi, obstructive enterocolitis, and death of 
the mice within 10 days (Ghosh et al. 2009). Depletion of HuR leads to a decline in actively 
proliferating progenitor cells, leaving quiescent stem cells and differentiated cells unaffected. 
Expression of p53 and its downstream effectors are upregulated after HuR deletion, 
suggesting that HuR controls p53 levels in progenitor cells, thus promoting survival (Ghosh et 
al. 2009). 
 
 
3.4 HuR in treatment of cancer 
 
Drug-resistance is a major problem in cancer treatment. A recent discovery is that several 
cancer drugs can work as activators for HuR, ones such as gemcitabine, paclitaxel, and 
tamoxifen. In estrogen receptor-expressing breast cancer cells, tamoxifen treatment causes 
inhibition of ER activity, but at the same time causes activation of JNK, leading to elevated 
cytoplasmic HuR expression and an HuR-mediated increase in stability of mRNAs important 
in drug-resistance and enhancement of cell survival (Hostetter et al. 2008). Similarly, in 
hormone-refractory prostate carcinoma cells, reduced miR-34 levels in the cells raise HuR 
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expression and enhance SIRT1 and Bcl-2 expression, leading to enhanced paclitaxel-
resistance (Kojima et al. 2010). In clinical ovarian cancer specimens, a strong correlation 
between cytoplasmic HuR expression and class III β-tubulin appears, and in ovarian cancer 
cells the cell responsiveness to cisplatin, paclitaxel, and tiocolchicine is restored by inhibiting 
class III beta-tubulin, which is also shown to be an HuR target (Raspaglio et al. 2010). 
Additionally, HuR binds the 3’UTR of p21 after irradiation and enhances its stability, 
suggesting that HuR can enhance p21 expression during radiotherapy, thus causing increased 
treatment-resistance by cancer cells. These examples all suggest that HuR regulation in cancer 
cells is important in the development of drug resistance. However, in pancreatic cancer cells, 
HuR overexpression can sensitize cells to gemcitabine treatment by raising the protein levels 
of deoxycytidine kinase, the enzyme that metabolizes and activates gemcitabine (Costantino 
et al. 2009); actually, patients with high cytoplasmic HuR expression survive better than do 
patients expressing low cytoplasmic HuR levels. 
 
The low molecular-weight inhibitors of HuR thus far developed have interfered with HuR-
RNA binding, HuR trafficking, cytokine expression, and T cell activation, and are 
antitumorigenic, antiangiogenic, and anti-inflammatory (Meisner et al. 2007). However, it 
remains to be seen whether these compounds will make it into the clinics.  
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AIMS OF THE STUDY 
 
 
This study was undertaken to elucidate the role of HuR in breast carcinogenesis. 
 
 
The specific aims of the projects were to: 
 
 
I Investigate the localization and clinicopathological significance of HuR protein 
expression in breast cancer. 
 
 
II Explore the association of HuR with clinicopathological variables and its 
prognostic significance in hereditary breast cancers. 
 
 
III Elucidate the localization and significance of HuR expression in ductal in situ 
carcinoma and study the role of HuR in breast carcinogenesis in vitro. 
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MATERIALS AND METHODS 
 
For each method, the relevant original publications are referred to by their Roman numerals. 
 
1. Patient material (I, II, III) 
 
This study utilized paraffin-embedded tissue material from women with sporadic invasive 
ductal breast carcinoma (I), a family history of breast cancer (II), DCIS (III), ADH (III), and 
from women with healthy tissue (III) from breast reduction surgeries. Detailed description of 
the patient materials is in the original publications.  
 
The study projects were performed with the informed consent of patients as well as 
permission from the Ethics Committee of the Helsinki University Central Hospital and from 
the Ministry of Social Affairs and Health in Finland. 
 
 
2. Immunohistochemistry (I, II, III) 
 
HuR protein expression was analyzed in the breast tissue specimens by immunohistochemical 
staining. From the formalin-fixed and paraffin-embedded breast tissues, 5-µm sections were 
cut and processed for immunohistochemistry.  
 
The immunostaining protocol of human specimens for HuR was carried out as follows: 
Specimens were deparaffinized and antigen retrieved by use of a microwave oven (4 x 5 min 
in 700 W in 0.01 M Na-citrate buffer at pH 6.0 for sporadic and familial breast cancer 
specimens and Tris-HCl at pH 8.5 for DCIS, ADH, and normal breast specimens). Tissues 
were immersed in 0.6% hydrogen peroxide in methanol for 30 min to prevent endogenous 
peroxidase activity and in blocking solution (1.5:100 normal horse serum in PBS) for 15 min 
to block unspecific binding sites. Immunostaining for HuR was performed with monoclonal 
antibody 19F12 (a kind gift of Dr. Henry Furneaux, University of Connecticut Health Center, 
Farmington, CT, USA), which was raised against a unique peptide from the NH2 terminus of 
HuR, at a dilution of 1:20,000 (0.5 µg/ml; sporadic breast cancer specimens) or 1:10,000 (1.0 
µg/ml; familial breast cancer, DCIS, ADH, and normal breast specimens) in PBS containing 
0.1% sodium azide and 0.5% BSA. Additionally, DCIS material was immunohistochemically 
stained with HuR 3A2 antibody at a dilution of 1:1000 (Santa Cruz Biotechnology, Inc., Santa 
Cruz, CA, USA). The specimens were incubated with antibodies at room temperature 
overnight. The sections were then treated with biotinylated horse antimouse immunoglobulin 
(1:200; Vector Laboratories Inc., Burlingame, CA, USA) and avidin-biotin peroxidase 
complex (Vectastain ABComplex, Vector). The peroxidase staining was visualized with 3-
amino-9-ethylcarbazole (Sigma-Aldrich, Inc., St. Louis, MO, USA), and the sections were 
counterstained with Mayer’s hematoxylin. In sporadic breast cancer material, to confirm the 
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specificity of the staining, a subset of the specimens (n = 7) was restained with and without 
the antigenic peptide for 19F12 (10 µg/ml; Clongene LLC, Hartford, CT, USA) for 1 h at 
room temperature before the staining procedure. To control the quality of HuR staining, each 
staining set contained predetermined breast or colon carcinoma specimens. 
 
For mouse mammary gland tissue samples, the protocol was identical except that the 
specimens were pretreated with Vector M.O.M. The Basic Immunodetection Kit (Vector), 
which blocks endogenous immunoglobulins in mouse tissue and enables the use of mouse 
monoclonal antibody. The 19F12 HuR antibody was used at a dilution of 1:20,000 (0.5 
µg/ml). 
 
 
3. Evaluation of immunostaining (I, II, III) 
 
HuR immunoreactivity was scored for each breast specimen independently and in a blinded 
manner by two investigators (M. H. and A. R.). HuR immunostaining was scored based on 
cytoplasm-negative, low-intensity cytoplasmic HuR staining present (visible at 100x or higher 
magnification), high intensity cytoplasmic HuR staining present (visible at 50x or lower 
magnification). Each staining set of 20 specimens contained two predetermined colon or 
breast carcinoma control slides, one of which contained only nuclear staining in the tumor 
cells and another one with additional cytoplasmic immunopositivity. All specimens with 
discordant scores were reevaluated by the two investigators using a multiheaded microscope, 
and the consensus score served for further analyses. 
 
 
4. Tissue cultures (III) 
 
The 184B5Me human mammary epithelial cell line was obtained by the transfecting parental 
184B5 cell line with the erbB2 oncogene and selecting colonies that grew anchorage-
independent (a kind gift of Dr Martha Stampfer, University of California, Berkeley, CA, USA 
and based on Novak et al. 2009). 184B5Me cells were cultured in MCDB 170 growth 
medium (US Biological, Swampscott, MA, USA) supplemented with 5 ng/ml epidermal 
growth factor, 0.5 µg/ml hydrocortisone, 5 µg/ml insulin, 70 µg/ml bovine pituitary extract, 5 
µg/ml transferrin, 10-5M isoproterenol, 50 µg/ml amphotericin B, and 50 µg/ml gentamicin 
(all reagents from Sigma-Aldrich Inc.). 293FT and MCF7 cells were cultured in DMEM 
medium supplemented with 10% fetal calf serum, L-glutamine, and antibiotics. All cells were 
cultured at 37 °C at 5% CO2. 
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5. Production of HuR-silencing (III) and -overexpressing constructs (unpublished 
data) 
 
To silence HuR expression in the cells, a lentiviral HuR shRNA construct was developed. 
Short hairpin RNAs (shRNA) are formed from siRNAs with a stem-loop hairpin structure; 
shRNA is inserted into an expression vector and transfected into cells where it can form 
functional siRNAs. For planning HuR shRNA oligos we used Applied Biosystem’s Ambion 
siRNA Converter software (www.ambion.com/techlib/misc/psilencer_converter.html). Our 
best working HuR siRNA sequences (target sequence: 5’-
AACATGACCCAGGATGAGTTA-3’) were entered into the software with loop-structure 
(TTCAAGAGA) and plasmid (pSilencer), after which the Ambion siRNA converter produces 
the sequences for HuR shRNA oligos. The control shRNA construct expressed a nontargeted 
scrambled sequence of an HuR shRNA oligo sequence (SCR shRNA). The oligos for HuR 
and SCR shRNA are presented in Table 4. The shRNA oligos were annealed with PCR (95 °C 
for 4 min, 70 °C for 10 min, 0.3 °C/sec until the temperature reached 4 °C) and ligated into a 
pENTR-H1-BgH entry plasmid. Ambion siRNA Converter software generates BamHI 
(5’G•GATCC3’) and HindIII (5’A•AGCTT3’) restriction sites to the ends of the oligos, 
which enables direct ligation (15 °C overnight) to the entry plasmid.  
 
To produce the shRNA sequence-containing entry plasmid, Stbl3 One Shot Chemically 
Competent E. coli (Invitrogen, Carlsbad, CA, USA) cells were transformed by heat shock (45 
sec at 42 °C) and plated on LB agar supplemented with Kanamycin (50 µg/mL, Sigma-
Aldrich) and incubated at 37 °C overnight. Several colonies formed were chosen for 
cultivation following plasmid purification by the Macherey-Nagel Plasmid DNA Purification 
Kit (Macherey-Nagel GmbH & Co, Düren, Germany). Correctness of the isolated plasmids 
was checked by test restrictions and sequencing. After confirming the right products, the 
shRNA sequence was transferred to the end plasmid (pDSL_hpUGIH) with LR 
recombination. The LR recombination reaction (entry clone 75 ng, destination clone 150 ng, 
LR clonase enzyme, 5x LR clonase TM reaction buffer, TE buffer pH 8.0, total volume 5 µl 
per reaction, Invitrogen) was incubated at room temperature overnight, after which proteinase 
K was added to inactivate endogenous nucleases. Stbl3 One Shot Chemically Competent E. 
coli (Invitrogen) cells were used again for transformation as above. The quality of the 
constructs was defined before continuing to virus particle production. 
 
To produce HuR overexpressing construct, the HuR coding sequence was copied from the 
pZeoSV2-HuR (sense) plasmid (kind gift of Dr. Myriam Gorospe, NIH, Baltimore, MD, 
USA) by PCR (98 °C for 30 sec following 30 cycles of 98 °C for 5 sec, 52 °C for 30 sec, and 
72 °C for 15 sec, after which 5 min at 72 °C and held at 4 °C; Table 4). The molar ratio 1.5:1 
was used for directional TOPO® cloning to introduce HuR cDNA into the pENTR™/D-
TOPO® entry-vector, and transformed to the TOP10 One Shot Chemically Competent E. coli 
cells (Invitrogen) by heat shock (30 sec at 42 °C). After selection and validation of an 
appropriate clone, LR recombination was performed as above. The destination vector was 
pLenti6/V5 (Invitrogen). 
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Table 4. Primers for HuR silencing and overexpression constructs. 
Construct Primer sequence 
HuR shRNA 
     Forward 
 
     Reverse 
 
5'-GATCCG CATGACCCAGGATGAGTTA TTCAAGAGA 
TAACTCATCCTGGGTCATG TTTTTTGGAAA-3' 
5'-AGCTTTTCCAAAAAA CATGACCCAGGATGAGTTA 
TCTCTTGAA TAACTCATCCTGGGTCATG CG-3' 
SCR shRNA 
     Forward 
 
     Reverse 
 
5'-GATCC GAACTTCGCGATGGATACA TTCAAGAGA 
TGTATCCATCGCGAAGTTC TTTTTTGGAAA-3' 
5'-AGCTTTTCCAAAAAA GAACTTCGCGATGGATACA 
TCTCTTGAA TGTATCCATCGCGAAGTTC G-3' 
HuR 
     Forward 
     Reverse 
 
5’ CACCGACTCACTATAGGGA 3’ 
5’ TTTGTGGGACTTGTTGGT 3’ 
 
 
6. Virus particle production (III) 
 
The lentiviral particles were produced by transfecting 293FT cells with Lipofectamine 2000 
(Invitrogen) containing a mixture of three plasmids: an HuR expression-modifying vector or 
its control vector (20 µg), a packaging plasmid (CMVdelta8.9, 15 µg), and a VSVg-coding 
envelope vector (pHCMV-G, 10 µg). Transfections were performed as follows: in tube A, 45 
µg of plasmid DNA mix and in tube B, 112 µl of Lipofectamine 2000 was added to 2800 µl 
of plain cell culture media. These tubes were incubated separately for 5 minutes at RT, after 
which they were combined, mixed by flicking of the tube, and incubated for 20 minutes at 
RT. Then 19 ml complete growth media without antibiotics was added onto the plasmid 
DNA-Lipofectamine media, and mixed by inverting the tube. Eight ml of this mix was added 
to 293FT cells (10 cm ∅) and incubated at 37 °C in 5% CO2 for 5 hours, after which the 
complete growth media was changed. Transfected 293FT cells were cultured for 72 hours at 
37 °C in 5% CO2, after which the supernatant was collected, sterile-filtered, and used directly 
on cell infections or stored at -80 °C. 
 
 
7. Cell infection with virus particles (III) 
 
A spin-down method was used to infect cells. Cells were seeded on a 6-well plate, and on the 
following day, virus infection was performed. Briefly, cells were incubated with virus particle 
media containing 8 µg/ml polybrene for 10 minutes at 37 °C in 5% CO2, centrifuged 
(Multifuge 3 S-R, Sorvall/Heraeus) at 2500 rpm for 30 minutes at RT, and incubated again at 
37 °C in 5% CO2 for 2 hours, after which the complete growth medium was changed on the 
cells. Cells were cultured at 37 °C in 5% CO2 for 72 hours, after which selection was started 
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with Hygromycin B (200 µg/ml for HuR shRNA, Invitrogen) or Blasticidin (5 µg/ml for HuR 
cDNA, Invitrogen). 
 
 
8. Cell transfections (III) 
 
Two HuR siRNA were used for 184B5Me breast epithelial cell transfections. The first HuR 
siRNA (Marked: siHuR1, target sequence: 5’-AACATGACCCAGGATGAGTTA-3’, 
Dharmacon, Thermo Scientific, Lafayette, CO, USA) sequence is the same that we used to 
produce the HuR shRNA construct. The second siRNA against HuR, ON-TARGET plus 
SMARTpool (Marked: siHuR2, Dharmacon, Thermo Scientific), is a siRNA pool containing 
four separate siRNA sequences against HuR, but not the siHuR1 sequence. The control 
siRNA was ON-TARGET plus Non-targeting Pool (Dharmacon, Thermo Scientific). 
 
Cells were seeded on 6-well plates in antibiotic-free media. On the following day, cells were 
treated with 100 nM siRNA targeting HuR or with control siRNA using Lipofectamine 2000 
(Invitrogen), double the amount recommended in the manufacturer’s instructions. Cells were 
incubated with siRNAs for 4 hours at 37 °C in 5% CO2, after which the complete growth 
media was changed. Incubation was continued for 72 hours at 37 °C, and mRNA and proteins 
were isolated. 
 
 
9. HuR immunofluorescence (III) 
 
184B5Me cells were fixed with 4% paraformaldehyde for 20 minutes at RT, permeabilized 
with 0.5% NP40-PBS for 5 minutes at RT, and blocked with 3% bovine serum albumine 
(BSA) in Tris-buffered saline (TBS) for 20 minutes at RT. HuR 19F12 primary antibody 
(Santa Cruz Biotechnology) was in a dilution of 1:200 in 3% BSA-TBS and incubated at 37 
°C for 75 minutes. Alexa-fluor® goat anti-mouse 546 IgG secondary antibody (Invitrogen) 
was used at a dilution of 1:200 at 37 °C for 45 minutes, and cells were mounted with the 
Vectashield Mounting Medium (Vector). 
 
 
10. Protein extractions and Western blot analysis (I, III) 
 
Mouse mammary glands were dissected from CD1 wild-type mice and from CD1 COX-2 
transgenic mice (Liu et al. 2001) and homogenized in an extraction buffer containing 1% 
Tween 20, following Western blot analysis using 60 µg of protein. A monoclonal 19F12 HuR 
antibody was used at a 1:10,000 dilution, and COX-2 was detected by a monoclonal antibody 
at a 1:5,000 dilution. Loading was controlled with ß-actin antibody (1:10,000 dilution; Santa 
Cruz Biotechnology). 
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Total proteins were isolated with a radioimmuno precipitation assay (RIPA) –buffer (150 mM 
NaCl, 1% NP-40, 1% DOC, 0.1% SDS, 50 mM Tris-HCl pH 8.0, 1 mM EDTA pH 8.0) with 
proteinase inhibitors or a NucleoSpin® RNA/protein kit (Macherey-Nagel GmbH & Co) 
using 1x Laemmli buffer (60 mM Tris-HCl pH 6.8, 2% SDS, 10% glycerol, 1% 2-
mercaptoethanol, 0.002% bromphenolblue). Cytoplasmic and nuclear fractions were prepared 
from cell cultures by use of an NE-PER nuclear and cytoplasmic extraction kit (Pierce 
Biotechnology, Rockford, IL, USA). Protein concentrations were measured in the lysates with 
a spectrophotometer (Multiscan Ascent, Thermo Labsystems). Proteins were separated on 
12% SDS-PAGE and transferred onto Hybond-C extra nitrocellulose membranes (Amersham, 
Buckinghamshire, UK). Nonspecific binding was blocked by incubating membranes in a 5% 
non-fat dry milk TBS-NP40 (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% NP-40) solution 
overnight at 4 °C. Membranes were incubated in primary and secondary antibodies for one 
hour at room temperature. Primary antibodies were mouse monoclonal rabbit polyclonal 
ATF-2 (1:100), mouse monoclonal CTGF (1:50), HuR 3A2 (1:2000), rabbit polyclonal Rab31 
(1:50), rabbit polyclonal anti-β-tubulin (1:500), goat polyclonal anti-β-actin (1:1000, all these 
antibodies from Santa Cruz Biotechnology), rabbit polyclonal HER-2 (1:1000, Upstate, Lake 
Placid, NY, USA), and rabbit polyclonal anti-lamin A/C (1:500, Cell Signaling Technology, 
Inc., Danvers, MA, USA). Secondary antibodies used were goat anti-mouse (1:2000 for HuR, 
1:500 for CTGF, Pierce Biotechnology, Rockford, IL, USA), goat anti-rabbit (1:500, Pierce), 
and donkey anti-goat (1:2000, Santa Cruz Biotechnology). 
 
 
11. RNA isolation and Real-Time Reverse Transcriptase Polymerase Chain 
Reaction (RT-PCR, III) 
 
RNA was isolated with the NucleoSpin® RNA/protein kit (Macherey-Nagel GmbH & Co). 
One microgram of RNA was converted to cDNA with M-MLV (moloney-murine leukemia 
virus) reverse transcriptase (Promega, Madison, WI, USA) and by random primers 
(Invitrogen) for 1 hour at 37 °C in a volume of 50 µl. The reaction was stopped by heat 
inactivation (95 °C for 3 minutes) and filled with sterile water to a final volume of 200 µl. 
Quantitative RT-PCR gene expression assays were performed with the GeneAmp 7500 
Sequence detection system according to the manufacturer’s protocol (Applied Biosystems, 
Foster City, CA). Briefly, a PCR reaction-master mix was prepared for each reaction: 1.25 µl 
of 20x target assay mix (target gene), 1.25 µl of endogenous control, 8 µl of RNAse-free 
water, and 12.5 µl of 2x TaqMan Universal PCR MasterMix. Then 23 µl of PCR master mix 
and 2 µl of cDNA template were pipeted per reaction (total volume 25 µl). PCR cycling 
conditions were as follows: 50 °C for 2 minutes, 95 °C for 10 minutes, followed by 40 cycles 
of 95 °C denaturation for 15 seconds and 60 °C annealing for 1 minute. ATF2 
(Hs00153179_m1), COX-2 (Hs00153133_m1), CTGF (Hs00170014_m1), DPYD 
(Hs01115751_m1), E-cadherin (Hs00170423_m1), ErbB2 (Hs01001580_m1), GRB14 
(Hs00610306_m1), HuR (Hs00171309_m1), MTUS1 (Hs00826834), p21 (Hs00355782_m1), 
p53 (Hs00153349_m1), PRKD1 (Hs01554327_m1), Rab27a (Hs00608302_m1), Rab31 
(Hs00924848_m1), Snail (Hs00195591_m1), Slug (Hs00161904_m1), TFPI2 
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(Hs00197918_m1), Twist (Hs00361186_m1), VCAN (Hs00171642_m1), Vimentin 
(Hs00185584_m1), Zeb1 (Hs00170423_m1), and Zeb2 (Hs00207691_m1) TaqMan® gene 
expression array primers (Applied Biosystems) were used, with human 18S rRNA as an 
endogenous control. Each sample had three replicates, and data were analyzed by the delta-
delta method to compare relative expression results (2-ddCt).  
 
 
12. mRNP immunoprecipitation for HuR (III) 
 
HuR binding to its possible mRNA targets was studied in 184B5Me breast epithelial and 
MCF7 breast cancer cells. Endogenous RNA protein complexes were immunoprecipitated 
(IP) from the cell lysates with a 50% (v/v) suspension of Protein A-Sepharose beads (Sigma-
Aldrich) precoated with 30 µg of either anti-HuR antibody (Santa Cruz Biotechnology) or 
IgG1 control (BD Pharmingen). The beads were washed with NT2 buffer: 50 mM Tris pH 
7.4, 150 mM NaCl, 1 mM MgCl2, 0.05% Nonidet P-40. For the analysis of RNAs in the IP, 
100 µl of NT2 buffer supplemented with 5 µl DNase I (2U/µl) were added to the beads, 
incubated at 37 °C for 10 min, washed with NT2 buffer, and further incubated with 100 µl of 
NT2 buffer containing 5 µl of Proteinase K (10 mg/ml) and 1 µl of 10% SDS at 55 °C for 30 
min. RNA was isolated and precipitated in the presence of glycoblue with acid phenol-CHCl3, 
sodium acetate, and ethanol.  
 
The mRNA levels of ten target genes were studied in MCF-7 and 184B5Me cell lines using 
PCR. GAPDH served as an endogenous control, and results were normalized to it. PTMA and 
EIF4EBP2 were positive controls. Primers for the qRT-PCR are presented in Table 5. 
 
 
Table 5. Primers to study HuR binding with its possible target mRNAs by qRT-PCR. 
Gene name Forward primer Reverse primer 
ATF-2 ACCATGCCTGTTGCTATTCC CCTGGAACACTAGGCACCAT 
CTGF TCCCACCCAATTCAAAACAT TGCTCCTAAAGCCACACCTT 
DPYD CGGGGAGTCGTGATTGTACT GTTCCATCTCCTCAGGGACA 
EIF4EBP2 CTTCCCTTTGTCTCCCATGA TCACACAGGACTGCCTCAAG 
GAPDH TGCACCACCAACTGCTTAGC GGCATGGACTGTGGTCATGAG 
GRB14 CTCTGCCACAAACATGGCTA CCCGTACCAAGAAAACTCCA 
MTUS1 GGACAACAACACAGCATTGG GGAAAGCTGCCTTGAGATTG 
PRKD1 GCCATGACCCTACCTCTGAA TGGGGACGAATCTGAAAGTC 
PTMA CCAACCCAAACCATGAGAA GGTCACACCACAAGTAAAGTCAG 
RAB27A ATCACAACAGTGGGCATTGA CCCTGCTGTGTCCCATAACT 
RAB31 CGCAAAAGTCAGGAAAGAGG GTGTTTCCCAGCCTTCACAT 
TFPI2 CGCACCAAAGAAAATTCCAT ATTGTCATTCCCTCCACAGC 
VCAN TGTTCCTCCCACTACCCTTG CTTCCACAGTGGGTGGTCTT 
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13. Cell growth measured by CellTiterBlue (III) 
 
To measure cell growth on two-dimensional cultures, the fluorometric method 
CellTiterBlue® Cell Viability Assay (Promega Corporation, Madison, WI, USA) was the 
choice. In the assay, the viable cells are able to reduce the indicator dye resazurin to resorufin, 
which is highly fluorescent. Cells were seeded on 96-well plates (1x103 cells / well in 100 µl 
media). On the measuring day, 20 µl per well of resazurin-containing reagent was added to 
cells then incubated at 37 °C in 5% CO2 for 2 hours, and the amount of fluorescent signal was 
measured with the FLUORstar OPTIMA Microplate Reader (BMG LABTECH Inc., Durham, 
NC, USA). Cell growth was measured on days 1, 4, and 7 after plating. 
 
 
14. Cell growth measured by cell counting (unpublished data) 
 
Cells (1x104 / well) were seeded in 2 ml of complete growth media in 6-well plates, and the 
number of cells was counted on days 1, 4, and 7 after the plating with a Bürker counting 
chamber. The experiment was repeated twice, and three parallel samples were counted per 
cell line per experiment. 
 
 
15. Anchorage-independent growth in soft agar (III) 
 
Cells (1x104 / ml) were suspended in 1 ml of 0.25% agarose (GellyPhor, EuroClone Spa, 
Pero, Italy), layered over 1 ml of 0.5% agarose base layer and supplemented with 2 ml 
complete culture medium in a 6-well plate. After 10 days of culture in agarose, cells were 
fixed with methanol for 10 minutes and stained with Giemsa (1:20 dilution in H2O, Sigma-
Aldrich Chemie GmbH, Buchs, Switzerland). Cell colonies were photographed with a Leica 
MZFLIII microscope with 3.2x enlargement and analyzed with ImageJ Software, taking 400 
pixels as a cut-off for colonies. Colonies from the transient transfections were counted 
manually from the pictures. 
 
 
16. Programmed cell death (anoikis) assay in methylcellulose (III) 
 
Cells (5x104 / ml) were suspended in 3 ml of 0.5% methylcellulose (Sigma-Aldrich) complete 
growth media mix, and seeded on bacterial plates (35 mm in diameter, Greiner-Bio One 
GmbH, Frichkenhausen, Germany), three plates per cell line. Cells were cultured in 0.5% 
methylcellulose media mix for 9 days, after which formed cell clusters were counted. 
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17. Cell senescence assay (unpublished data) 
 
Cell senescence was studied in the 184B5Me HuR-silenced cells and their controls with the 
Senescence Detection Kit (Biovision, Inc., Mountain View, CA, USA), which 
histochemically detects the expression of β-galactosidase (SA-β-Gal) activity. Cells were 
fixed with Fixative Solution for 10 to 15 minutes at RT, stained with the Staining Solution 
Mix overnight at 37 °C; development of blue color was detected with a light microscope. 
 
 
18. Cell invasion assay using myoma organotypic culture (III) 
 
We studied HuR-silenced cells and their controls’ invasion ability in a myoma organotypic 
culture model (Nurmenniemi et al. 2009). Briefly, macroscopically homogeneous areas of 
uterine leiomyoma tissue were used to prepare myoma disks for the experiment. These disks 
were stored in 10% DMSO at -70 °C. To start the myoma organotypic culture, myoma disks 
were first equilibrated in the complete growth media of the cells at 4 °C with gentle rocking 
for 10 days. Equilibrated myoma discs were placed into Transwell inserts (6.5 mm in 
diameter; Corning Incorporated, Corning, NY, USA), and 5 x 105 HuR-silenced cells or 
control cells were seeded on the myoma disks in 50 µl of culture media. The cells were 
allowed to attach overnight, after which the disks removed from the Transwell inserts were 
transferred onto uncoated nylon disks resting on curved steel grids (3 mm x 12 mm x 15 mm) 
on 12-well plates in 1 ml of culture media. Myoma organotypic cultures were maintained at 
37 °C for 10 days, and the media of the cultures were changed every 3 days. In the 
experiment, the disks prepared were from the same myoma. 
 
At day 10, the organotypic cultures were fixed in 4% neutral-buffered formalin overnight, 
after which they were dehydrated, bisected, and embedded in paraffin. Mayer’s hematoxylin 
and eosin, and pancytokeratin AE1/AE3 (1:150 dilution; Dako, Glostrup, Denmark) 
immunohistochemistry allowed identification of invaded cells.  
 
 
19. In vivo mouse experiment (III) 
 
HuR-silenced cell and control cell tumorigenity was studied in immunodeficient mice. This 
study was an outsourced service conducted at Pharmatest Services Ltd, Turku, Finland. The 
Hsd:Athymic Nude-Foxn1nu mouse strain (supplier: Harlan, Boxmeer, the Netherlands) was 
maintained at the Turku Science Park Biolaboratory (License: STO/1053 (8.9.1999), 
1132/712-92, 1286/712-86). Five million cells in 120 µl cell culture media containing 30% 
Matrigel were orthotopically inoculated into the mammary fat pads of the female mice. Each 
group comprised 10 mice; HuR-silenced cells were inoculated into 18 mammary glands, but 
control (shSCR) cells into only 11 mammary glands because of an insufficient quantity of 
cells. The mice had free access to food and water. Tumor diameters were measured once a 
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week with a caliper and tumor volume was calculated according to the formula (π/6)(d1xd2)3/2, 
where d1 and d2 are perpendicular tumor diameters. The experiment continued for 12 weeks. 
 
The experimental procedures were reviewed by the local Ethics Committee on Animal 
Experimentation at the University of Turku and approved by the local Provincial State Office 
of Western Finland (Licence: ESLH-2008-00340-Ym23). 
 
 
20. Gene expression array (III) 
 
GeneChip® Human Genome U133 plus 2.0 (Affymetrix Inc., Santa Clara, CA, USA) gene 
expression arrays were performed on the 184B5Me cells infected with the HuR-silencing 
construct and its control (n = 2 per cell line) at the Biomedicum Biochip Center 
(www.helsinki.fi/biochipcenter). Gene expression arrays were analyzed with CSC Chipster 
v1.3.0 software for DNA Microarray data analysis (http://nami.csc.fi). Microarray data were 
normalized by the gcrma (GeneChip Robust Multi-array Average) normalization method. The 
probes were re-annotated by use of alternative chip description file (CDF) environments 
(hs133phsentrezg (hgu133plus2)). In the re-annotation process, ambiguous probes that map to 
more than one position in the genome were discarded. This left 17 589 probe-sets for the 
further analyses. Data were further preprocessed, filtering genes according to their standard 
deviation, i.e. genes that show the lowest standard deviations are those that display little 
difference between HuR-silenced cells and their controls, and are filtered out. Cut-off point 
for the data to be filtered out was 95%. For statistical analyses, a two-group test was used 
with the settings empirical Bayes t-test, and the Benjamin-Hochberg false discovery rate for 
correcting multiple tests; the p-value cut-off was 0.01. For overexpressed transcripts, we 
selected only those induced by two-fold or higher, and for under-expressed those that were 
0.5-fold or lower. 
 
 
21. Cell network analysis (III) 
 
The Moksiskaan (Laakso et al. 2010) computational platform allowed study of biological 
alterations in the cells after HuR silencing. The Moksiskaan integrates pathway, protein-
protein interaction, drug target, and disease information from various databases. This 
information is compared to the given set of differentially expressed genes (DEGs) in order to 
describe their biological function and cross-links in the cells. Expression arrays were re-
analyzed within the system to obtain the latest genome annotations and to make the data 
formats compatible with the tools. Genes with a fold change less than 1/1.5 were considered 
as down- and those > 1.5 as upregulated. 
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22. Statistical analysis (I, II, III)  
 
The association between HuR staining and clinically relevant and prognostic variables was 
assessed by χ2 test. Life tables were computed according to the Kaplan-Meier method, and 
survival curves were compared with the log-rank test. Distant disease-free survival was 
calculated from date of diagnosis to occurrence of metastases outside the regional area or to 
death from breast cancer. Overall survival was calculated from date of the diagnosis to death 
from breast cancer. Patients who died from intercurrent causes were censored at the date of 
death. Multivariate survival analyses were performed with the Cox proportional hazards 
model. A backward stepwise algorithm aids in the choice of the best combination of 
prognostic factors to explain the mortality in the study population. Hazard ratios are provided 
for each covariate. Cox regression involved a backward stepwise selection of variables, and a 
p of 0.05 was adopted as the limit for inclusion of a covariate. The non-parametric Mann-
Whitney U-test served for the statistical analysis to compare the groups in cell growth, 
anchorage-independent growth, programmed cell death, and invasion assays. A p-value of ≤ 
0.05 was considered statistically significant. All data are shown as means ± SEM. The data 
was analyzed with SPSS for Windows v12.0.1 (SPSS Inc., Chicago, IL, USA) or with SPSS 
16.0 for Mac (SPSS Inc.). 
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RESULTS AND DISCUSSION 
 
Results of the thesis projects are summarized and discussed here. Project-specific detailed 
presentations and discussions are in the original publications, referred to by their Roman 
numerals. 
 
 
1. THE EXPRESSION AND PROGNOSTIC VALUE OF HUR IN THE BREAST (I, II, 
III). 
 
When this thesis project began, the first hints had been found of the significance of HuR 
expression to carcinogenesis. Gliomas (high-grade brain tumors) expressed elevated levels of 
nuclear HuR (Nabors et al. 2001), and chemically induced mice lung tumors expressed 
elevated levels of cytoplasmic HuR (Blaxall et al. 2000). Additionally, a prognostic role for 
HuR in ovarian cancer had been suggested (Erkinheimo et al. 2003, Denkert et al. 2004a). We 
used a mouse mammary gland tumor model, where the human COX-2 gene is overexpressed 
under the influence of a murine mammary tumor virus promoter (Liu et al. 2001), to study the 
expression of HuR in mouse mammary gland tumors. We found that formed breast tumors 
expressed higher levels of HuR than did healthy mammary gland tissue from wild-type 
control mice. Immunohistochemical analysis of these cancerous and healthy mice mammary 
gland tissues revealed that HuR expression had translocated to the cytoplasm in cancerous 
mammary glands, whereas in wild-type control mice its expression was mainly nuclear. Since 
cytoplasmic HuR mediates mRNA stabilization and translation of cancer-promoting genes 
(Abdelmohsen et al. 2010a), these results raised the question whether HuR is expressed in 
human breast cancer. 
 
 
1.1 Expression of HuR in clinical specimens from the breast 
 
We studied the expression and localization of HuR in healthy breast tissue, in preinvasive 
breast cancer lesions (ADH, DCIS) and in invasive sporadic ductal breast carcinoma and 
familial breast cancer specimens. ADH and DCIS associate with an increased risk for invasive 
breast cancer (RR of 4.0-5.0 for ADH and 10-12 for DCIS) (Tavassoli et al. 2003), and if left 
untreated, 14 to 75% of DCISs can proceed to invasive breast cancer (Mokbel et al. 2006). 
Although non-invasive, some genetic alterations have already occurred in ADH and DCIS 
that are comparable to changes in invasive breast cancer, such as loss of heterozygosity 
(Tavassoli et al. 2003). Currently, we have no method to separate from the preinvasive cases 
the ones, which will develop into an invasive breast cancer, which is the reason that surgery 
and clearance of axillary lymph nodes are performed as treatment for all the patients. Invasive 
ductal breast cancer (of no specific type) is the most common breast cancer type in women, 
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comprising 40 to 75% of all breast cancer cases (Tavassoli et al. 2003), and familial breast 
cancer comprises approximately 10% of all breast cancers (Venkitaraman 2002).  
 
Mutations in two breast cancer susceptibility genes, BRCA-1 and BRCA-2, predispose women 
to breast cancer. In BRCA-1 mutation carriers, the cumulative risk for developing breast 
cancer before 70 years of age is 50 to 70%, and in BRCA-2 mutation carriers, 40 to 50% 
(Venkitaraman 2009). Mutations in BRCA genes, however, explain only about 15% of all 
hereditary breast cancers, and an additional 10% of the cases are connected to the effects of 
other known cancer susceptibility genes such as TP53, PTEN, ATM, and CHECK2. The 
remaining hereditary breast cancers are possibly a consequence of a polygenic model in which 
polymorphism or mutations in a large number of genes, each conferring a small excess of 
risk, have a magnifying effect (Venkitaraman 2009).  
 
 
Table 6. Cytoplasmic HuR expression in breast tissue specimens as detected by HuR 19F12 
antibody. 
 
Tissue N Cytoplasmic HuR Expression, N (%) 
Negative                         Positive 
Healthy breast tissue 66 57 (71) 19 (29) 
Atypical ductal hyperplasia 71 36 (51) 35 (49) 
Ductal carcinoma in situ 74 39 (53) 35 (47) 
Invasive ductal breast carcinoma 133 80 (60) 53 (40) 
Familial breast cancer 
Non-BRCA1/2 
BRCA-1 
BRCA-2 
 
525 
51 
47 
 
318 (61) 
19 (37) 
18 (38) 
 
207 (39) 
32 (63) 
29 (62) 
 
 
Our results show that cytoplasmic HuR expression is already aberrant in ADH cases and 
remains elevated also in DCIS as well as in invasive cancers (Table 6). Cytoplasmic HuR 
expression was higher in healthy controls (29%) than has been generally reported, < 10% 
(Wang et al. 2000b, Lopez de Silanes et al. 2003, Yuan et al. 2010), but the cytoplasmic 
expression pattern of HuR was focal and localized to the luminal epithelial cells of the acinar 
and ductal structures. This may show up in healthy controls as a relatively high proportion of 
cytoplasmic HuR expression, since in our scoring system, the highest score of the tissue 
specimen was always noticed in the analysis. A recent report showed that HuR expression in 
the endometrium varies during the menstrual cycle, being highest from mid-proliferative 
phases (days 6-14) till mid-secretory phases (days 15-23) (Karipcin et al. 2010). Similarly, in 
the breast, HuR may be under endo-, para- or autocrine control, which may explain the focal 
expression of HuR in the cytoplasm of healthy controls. ADH, DCIS, and invasive cancer 
specimens expressed cytoplasmic HuR uniformly, and the expression was localized in 
neoplastic epithelial cells. Stromal tissue remained negative for HuR staining or showed only 
partial nuclear positivity. We did not, however, analyze systematically the expression of HuR 
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in the stroma, so drawing too strong conclusions as to HuR expression in the stromal tissue 
would be unwise. 
 
 
1.2 Association of cytoplasmic HuR expression with clinicopathological 
parameters and survival 
 
Study of the association of cytoplasmic HuR expression with clinicopathological parameters 
and survival should elucidate the potential of HuR to serve as a prognostic marker. In DCIS, 
cytoplasmic HuR expression associated with high grade, prostaglandin receptor negativity, 
and microinvasive or tumor cell-positive sentinel node findings. Cytoplasmic HuR expression 
was associated in these preinvasive specimens with a more aggressive form of the disease and 
suggests that HuR participates in tumor development towards invasive disease. 
 
In invasive sporadic ductal breast carcinoma and familial non-BRCA1/2 cases, cytoplasmic 
HuR expression associated with p53 positivity, poorly differentiated tumors, and reduced 
disease survival. Additionally, in sporadic cases, large tumor size, and in familial non-
BRCA1/2 cases, ductal type and hormone-receptor negativity associated significantly with 
cytoplasmic HuR expression. Most importantly, cytoplasmic HuR expression was an 
independent marker for reduced survival in both sporadic and familial non-BRCA1/2 breast 
cancers, meaning that cytoplasmic HuR expression alone can predict disease prognosis. 
 
Additionally, we studied the prognostic capacity of cytoplasmic HuR expression in more 
detail by subgroup analysis. The data from these analyses show that high cytoplasmic HuR 
expression associated with reduced survival in the subgroups of older patient (age ≥ 50), small 
tumors (≤ 2 cm), poorly differentiated tumors, in lymph node-negative and -positive tumors, 
hormone-receptor-expressing tumors, and HER-2-negative tumors. This is an important 
finding, since especially in the subgroups of small and lymph node-negative tumors the need 
to forecast their individual course was immediate. 
 
Our BRCA-1 and BRCA-2 mutated specimens showed the highest cytoplasmic HuR positivity 
(Table 6). These proteins play a crucial role in maintaining structural and numerical stability 
of chromosomes by participating in DNA repair and recombination, cell cycle control and 
transcription (Venkitaraman 2002, 2009). Although having similar effects in cells, BRCA-1 
and BRCA-2 bear little similarity to each other or to proteins of known function 
(Venkitaraman 2009). Malfunctioning BRCA-1 or BRCA-2 protein leads to DNA damage in 
the cell, which causes increased cell stress. HuR is a cell stress-responsive protein and 
regulates many proteins involved in cellular response to DNA damage such as p21, p53, and 
cyclins A and B1 (Wang et al. 2000a, 2000b, Mazan-Mamczarz et al. 2003, Kim et al. 2010), 
which may explain the high cytoplasmic HuR expression found in BRCA-1 and -2 cases. 
Cytoplasmic HuR expression was associated only with p53 positivity in BRCA-1 cases. The 
reason for HuR’s not associating with these clinicopathological parameters and showing no 
prognostic capacity may be that DNA damage causes multiple alterations in the cells, leading 
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to loss of a single factor. Interestingly, in BRCA-1-mutated cases, patients who expressed 
HuR in their cytoplasm survived better than did HuR cytoplasm-negative patients. It would be 
interesting to study, whether HuR expression is aberrant in the healthy tissue of BRCA-
mutation carriers. However, since we had only tumor microarray specimens of these patients, 
we cannot draw any conclusions as to HuR expression even in adjacent tissue. HuR binds 
BRCA-1 mRNA and negatively regulates translation of the protein in vitro (Saunus et al. 
2008). In this respect, cytoplasmic HuR expression may prevent the translation of mutated 
BRCA-1 and formation of malfunctioning DNA repair machinery (O'Donovan et al. 2010). 
However, because this result was not statistically significant, and knowing that HuR can also 
regulate so many other targets in the cytoplasm that are beneficial for cancer development, 
strong conclusions are impossible. 
 
Our cytoplasmic HuR expression data for the breast specimens are in line with others’ 
findings in breast carcinoma specimens (30%-75%) (Denkert et al. 2004b, Woo et al. 2009), 
as well in colon (53%-96%), gastric (40%), and ovarian (45%-70%) cancer cases (Erkinheimo 
et al. 2003, 2005, Denkert et al. 2004a, 2006, Mrena et al. 2005, Yi et al. 2009, Young et al. 
2009), and HuR expression translocates from nuclear staining in healthy tissue to cytoplasmic 
staining in cancerous tissue (Lopez de Silanes et al. 2003, Koljonen et al. 2008, Niesporek et 
al. 2008, Barbisan et al. 2009, Young et al. 2009) Additionally, we found cytoplasmic HuR 
expression to associate with increased aggressiveness of the disease, and similarly an 
association has been commonly reported of cytoplasmic HuR expression with poorly 
differentiated tumors (Erkinheimo et al. 2003, 2005, Denkert et al. 2004a, 2004b, 2006, 
Niesporek et al. 2008, Stoppoloni et al. 2008, Barbisan et al. 2009). These results suggest that 
HuR translocation to the cytoplasm is important for breast cancer development and plausibly 
could serve as a prognostic marker in clinics. 
 
 
2. THE ROLE OF HUR IN BREAST CARCINOGENESIS (III) 
 
Clinical material results suggest a role for HuR in breast carcinogenesis. To explore the 
mechanisms by which HuR mediates carcinogenesis at its pre-invasive stage towards invasive 
breast cancer, we chose the 184B5Me breast epithelial cell line. This cell line was created by 
transfecting 184B5 breast epithelial cells with the erbB2 oncogene and selecting for 
anchorage-independent growth (Novak et al. 2009). We modulated HuR expression in these 
cells by infecting them with lentiviral constructs that silenced or overexpressed HuR 
expression (Figure 6). With these constructs, we were able to inhibit HuR protein expression 
in the cells efficiently, although overexpression of HuR protein in the cells was only modest 
(Figure 6A-C). At mRNA level, HuR expression was inhibited by 87% and overexpressed by 
2-fold (Figure 6D). 
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Figure 6. HuR expression in the modified 184B5Me cells. (A) Total protein expression, (B) 
nuclear HuR protein expression, and (C) cytoplasmic HuR protein expression in the cells. (D) 
qRT-PCR analysis of HuR levels in the modified cells. shSCR is a control cell line for 
silenced HuR cells (shHuR), and Control is a control for HuR-overexpressing cells (HuR). An 
arrow in A-C represents exogenous His-tagged HuR, and the band below this comes from the 
endogenous HuR protein expression. 
 
 
To study the malignancy of the cells, we performed an in vivo experiment in which HuR-
silenced 184B5Me cells (n = 10), and their controls (n = 10) were orthotopically inoculated in 
Matrigel into NUDE mice mammary fat pads; we monitored tumor formation for 12 weeks 
(Figure 7A). One control mouse showed slightly atypical cell growth in the mammary gland 
(Figure 7B) during this monitoring period, while in others, inoculated breast epithelial cells 
regressed, and connective tissue formation increased (Figure 7C). Based on this, we 
concluded that these cells do not form tumors in vivo, or they form them after a very long lag-
period (> 12 weeks). For this reason, we believe that the 184B5Me cell model is 
representative of DCIS, since these cells are readily transformed but are unable to form 
invasive tumors in in vivo conditions. This is thus a suitable model for study of the 
mechanisms of HuR in carcinogenesis of the breast. 
 
Results and Discussion 
 46 
 
 
Figure 7. HuR-silenced 184B5Me cells and their control cells growth in vivo. (A) HuR-
silenced 184B5Me cells and their control cells growth in the mice mammary glands during 
the 12-week monitoring period. (B) In one case, control cells showed DCIS-like growth in the 
mouse mammary gland. (C) Orthotopical inoculation of the breast epithelial cells in the mice 
mammary glands caused regression of the inoculated cells and increased connective tissue 
growth. 
 
 
2.1 Mechanisms of HuR to mediate carcinogenesis 
 
Neither overexpression nor silencing of HuR affected cell proliferation in two-dimensional 
cell culture conditions (Figure 8), suggesting that in this model HuR does not mediate 
carcinogenic properties by promoting cell growth. Quantitated RT-PCR analysis of COX-2, 
p21 and p53, genes that mediate cell survival and proliferation and are known targets for HuR 
regulation (Figure 5), support this hypothesis, since no differences emerged in the expression 
of these genes (data not shown). Moreover, our clinical DCIS data support this finding, since 
HuR expression did not associate with the proliferation marker MIB-1. However, HuR 
regulates expression of genes playing a role in cell survival, and altered HuR expression has 
been associated with changes in cell-growth properties (Dormoy-Raclet et al. 2007, Kang et 
al. 2008). Nevertheless, many of the studies have involved invasive cancer cells, and the role 
of HuR regulation may differ at the preinvasive stage from that in invasive cells, as also 
suggested by Mazan-Mamczarz et al. (2008a, 2008b) based on their results from breast 
epithelial and cancer cell microarray analysis. 
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Figure 8. Proliferation of HuR expression-modified 184B5Me cells. Proliferation of HuR-
silenced cells and their controls (A) and HuR-overexpressing cells and their controls (B) as 
measured by CellTiterBlue. (C) Proliferation of HuR-silenced cells and their controls was 
measured also by cell counting. (D) Transcient HuR siRNA transfections allowed detection of 
the immediate early effect of HuR silencing on cell proliferation. shSCR is a control cell line 
for silenced HuR cells (shHuR) and Control is a control for HuR-overexpressing cells (HuR); 
siCtrl is a control for HuR siRNA transfections, and siHuR1 and siHuR2 present the two 
different HuR siRNAs. 
 
 
Interestingly, HuR silencing reduced and overexpression increased cells’ ability to grow 
anchorage-independent (Figure 9A), suggesting that HuR participates in cell transformation 
and plays an important role in contact-independent growth in breast carcinogenesis. Our result 
is supported by the finding of Mazan-Mamczarz et al. (2008b) showing that HuR depletion in 
the MCF10A breast epithelial cell line causes a significant reduction in anchorage-
independent colony formation. Although when cell proliferation was studied in the cells’ 
actively growing phase the results showed no differences, we decided to investigate the 
possibility that HuR silencing leads more quickly to cellular senescence, a state in which cell 
replication has ended, since reduction of HuR expression in fibroblasts has been associated 
with this phenomenon (Wang et al. 2003). However, reduced colony formation after HuR 
silencing was not a consequence of cellular senescence caused by HuR depletion (Figure 9B 
and 9D); rather the diminished ability of HuR-silenced cells to grow anchorage-independently 
was, at least in part, due to increased anoikis, i.e. cell death caused by cell homelessness 
(Figure 9C). Interestingly, no differences were observable between HuR-overexpressing cells 
and their controls (Figure 9C), suggesting that normal HuR expression is sufficient to protect 
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cells from anoikis, whereas overexpression of HuR failed to enhance the protective effect. 
Although we did not study the mechanisms behind this detachment-induced cell death more 
carefully, Bcl-2, p53, and Fas receptor-mediated signaling pathways have been shown to 
mediate the progression of anoikis (Frisch et al. 2001, Grossmann 2002), all known target 
transcripts for HuR regulation (Mazan-Mamczarz et al. 2003, Abdelmohsen et al. 2007a, 
Izquierdo 2008, 2010, Ghisolfi et al. 2009). These are interesting observations, since when a 
cancer cell invades or metastasizes to a distant tissue it needs to overcome several challenges 
like growing in foreign surroundings and evading numerous death signals caused by anoikis 
and amorphosis (loss of contact with extracellular matrix, ECM) (Psaila et al. 2009). Thus 
this is the first time HuR expression is shown to play a role in anoikis. 
 
 
 
 
Figure 9. (A) HuR expression-modified 184B5Me cells’ ability to grow anchorage-
independent. (B) Cellular senescence in HuR-silenced control cells. (C) Programmed cell 
death caused by anoikis measured in HuR expression-modified 184B5Me cells. (D) Cellular 
senescence in HuR-silenced 184B5Me cells. In (B) and (D), black represents β-galactosidase 
positivity. Original magnification in (B) and (D) is 200x. 
 
 
Since HuR seemed to affect cell-ability to grow without contact with their surroundings, we 
investigated whether HuR silencing also affects cell motility. Since the microenvironment of 
the tissue affects cell behavior, we decided to use a myoma organotypic invasion model 
(Nurmenniemi et al. 2009), in which cells are allowed to invade in the uterine leiomyoma 
tissue in their own culture media without any stimuli. Leiomyoma tissue is composed of 
collagens, laminins, fibroblast, smooth muscle actin, lymphocytes, macrophages, and 
endothelial cells forming a more natural stroma-like environment for the epithelial cells. Our 
results show that HuR-silenced cells’ invasion ability was reduced by 25% compared to that 
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of the control cells. Similarly, in human breast and cervical carcinoma cells, HuR depletion 
reduces cell migration and invasion ability (Dormoy-Raclet et al. 2007, Woo et al. 2010). 
Since HuR regulates EMT by stabilizing Snail mRNA, which leads to an enhancement of cell 
migration through repression of E-cadherin expression in breast cancer cells (Dong et al. 
2007), the expression of common EMT-related genes was worth study. However, we found 
no differences in the expression of E-cadherin, Snail, Slug, Twist, Vimentin, Zeb1, Zeb2 or β-
catenin between HuR-silenced cells and their controls (data not shown). Since the traditional 
HuR targets studied show no difference in their expression and cannot explain the phenomena 
found, our results suggest a new model for HuR as to how it mediates cell transformation and 
promotes cell survival, and possibly also disease progression. 
 
 
2.2 Gene expression arrays and interaction analysis 
 
To better understand the role of HuR in breast carcinogenesis, we studied the effect of HuR 
silencing on gene expression profiling. Since we were primarily interested in HuR-
upregulated genes in breast carcinogenesis, we concentrated on those transcripts, whose 
expression was inhibited by shHuR. After strict elimination of the genes (p < 0.01, genes 
containing a putative HuR-binding motif, and playing a known role in breast carcinogenesis), 
we chose ten for further validation. Seven of the validated genes proved not to be direct 
targets of HuR binding, yet, since HuR silencing inhibits the expression of these genes, they 
are downstream targets of HuR regulation. However, we identified three genes (ATF2, CTGF, 
RAB31) to be direct binding targets of HuR based on an HuR-binding assay 
(immunoprecipitation). Interestingly, these genes have been linked to apoptosis, proliferation, 
migration, and invasion in breast cancer (Chen et al. 2007, Kotzsch et al. 2008, Knippen et al. 
2009). However, although these target genes mediated functions altered in this study, we 
cannot conclude that the main targets of HuR are any of these three genes, and actually a 
more likely scenario is that these results are a sum of several factors acting together.  
 
For a comprehensive picture of alterations in the breast epithelial cells caused by HuR 
silencing, gene network analysis followed using the computational platform Moksiskaan 
(Laakso et al. 2010). Biological processes affected after HuR silencing were related to 
epithelial cell development, cell adhesion, nucleosome assembly, wounding, response to 
chemical stimuli, and regulation of biological quality (Table 7). Kyoto Encyclopedia of genes 
and genomes (KEGG) pathway analysis incorporated genes that were altered after HuR 
silencing into joint pathways that supported the relationships between the genes. In 20 
pathways, significant (p ≤ 0.05) enrichment was noticeable in genes that showed altered 
expression after HuR silencing. Enriched KEGG pathways were the TGF-β-signaling 
pathway, steroid hormone biosynthesis, natural killer cell-mediated cytotoxicity, cytokine-
cytokine receptor interaction, apoptosis, metabolism of xenobiotics by cytochrome P450, 
ECM-receptor interaction, the Wnt-signaling pathway, glycerolipid metabolism, pathways in 
cancer, dilated cardiomyopathy, gastric acid secretion, amoebiasis, vasopressin-related water 
reabsorption, the complement and coagulation cascade, axon guidance, the p53 signaling 
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pathway, the MAPK signaling pathway, glycerophospholipid metabolism, and sphingolipid 
metabolism. For HuR, p53 and TGF-β are known targets (Nabors et al. 2001, Mazan-
Mamczarz et al. 2003). Similarly, HuR regulates transcripts related to the Wnt signaling 
pathway (Briata et al. 2003, Leandersson et al. 2006, Lee et al. 2006, Mukherjee et al. 2009), 
and kinases in the MAPK pathway play a role in HuR regulation as well participate in HuR-
mediated regulation (Tran et al. 2003, Lafarga et al. 2009, Abdelmohsen et al. 2010a). 
Mazan-Mamczarz et al. (2008a, 2008b) showed that the HuR association changes with a more 
tumorigenic phenotype: in breast epithelial cells, HuR enhanced expression of genes affecting 
pathways involved in cellular transformation, and later in breast carcinogenesis, HuR altered 
its mRNA interaction to genes promoting cancer development. Our data show that HuR 
regulates several target transcipts in the cells. Together these data suggest a multifactorial role 
for HuR in the cells as a regulator of several genes in different signaling pathways, and 
supports the hypothesis of HuR’s playing a role in carcinogenesis of the breast.  
 
 
Table 7. Altered biological processes after HuR silencing in 184B5Me cells.  
Description Ratio P-value Down-regulated genes Up-regulated genes 
Ectoderm 
development 
0.069 0.009 CTGF, FOXQ1, FST, KRT34, 
TGFB2 
AHNAK2, GRHL3, IVL, KRT1, 
KRT13, KRT16, KRT6B, S100A7, 
SPINK5, SPRR1A, SPRR1B 
 
Epidermis 
development 
0.065 0.009 CTGF, FOXQ1, FST, KRT34, 
TGFB2 
AHNAK2, GRHL3, IVL, KRT1, 
KRT13, KRT16, S100A7, SPINK5, 
SPRR1A, SPRR1B 
 
Cell adhesion 0.126 0.023 AMIGO2, CTGF, EPDR1, 
ITGA4, NRCAM, PCDH20, 
PPAP2B, PVRL3, S1PR1, 
SGCE, SPOCK1, SPP1, TGFB2, 
TNC, VCAN 
ARHGDIB, LY6D, CD36, CDH16, 
COL2A1, DSC1, DSC2, DSG1, 
FLRT3, GPNMB, PCDHB10, 
PKP1, SPINK5, WNT4 
 
Nucleosome 
assembly 
0.043 0.023 HIST1H4D, NAP1L3 HIST1H1C, HIST1H2AC, 
HIST1H2BC, HIST1H2BD, 
HIST1H2BF, HISTH2BK, 
HIST1H4H, RTN1 
 
Response to 
chemical 
stimuli 
0.208 0.023 AGPS, ANGPTL4, CCNA1, 
CMTM7, CPS, CTGF, CYP1B1, 
DKK1, DUSP4, DUSP6, EPS8, 
FKBP1B, GCLM, GNG11, 
GPAM, GRB14, HDAC4, 
HSD17B2, LIPG, MTUS1, 
PLOD2, PRKACB, S1PR1, 
SERPINA1, SPARC, SPP1, 
STEAP2, TGFB2 
 
ABCG1, ASS1, BLMH, CD36, 
CRYAB, CTSO, CYP1A1, 
CYP4B1, GAL, GUCY1A3, 
IL1RN, KRT1, KRT13, LCN2, 
LOX, S100A7, S100A8, S100A9, 
SULT1B1, WNT4 
Response to 
wounding 
0.113 0.023 CFH, CTGF, HDAC4, PPAP2B, 
RAB27A, S1PR3, SAAL1, 
SERPINA1, SPP1, TFPI2, 
TGFB2, TNC, VCAN 
 
ACE2, ASS1, CD36, CYP1A1, 
GAL, GRHL3, IFNGR1, IL1RN, 
KRT1, LOX, S100A8, S100A9, 
SERPINA3 
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Table 7. Altered biological processes after HuR silencing in 184B5Me cells continues.  
Description Ratio P-value Down-regulated genes Up-regulated genes 
Response to 
organic 
substances 
0.147 0.023 CCNA1, CPS1, CTGF, 
CYP1B1, DUSP4, DUSP6, 
EPS8, FKBP1B, GNG11, 
GPAM, GRB14, HDAC, 
MTUS1, PRKACB, SERPINA1, 
SPARC, SPP1, STEAP2, 
TGFP2 
 
ABCG1, ASS1, CD36, CRYAB, 
CTSO, CYP1A1, GAL, 
GUCY1A3, IL1RN, LCN2, LOX, 
S100A7, S100A8, S100A9, WNT4 
Response to 
herbicides 
 
0.013 0.031  CYP1A1, GUCY1A3, LCN2 
Phospholipid 
homeostasis 
 
0.013 0.038 GPAM, LIPG ABCG1  
Regulation of 
biological 
quality 
0.216 0.038 ANGPTL4, CDA, CPS1, CTGF, 
CYP1B1, FKBP1B, FST, 
GABRA2, GCLM, GPAM, 
IGFBP6, LIPG, NRCAM, 
PPAP2B, RAB27A, S1PR1, 
S1PR3, SERPINA3,1, SHISA9, 
SLC22A4, SLC30A7, SOAT1, 
SPP1, TFPI2, TGFB2, TMX3 
 
ABCG1, ACE2, CALB1, CD36, 
COL2A1, CRYAB, CYP1A1, 
DSG1, FGFR3, GAL, GUCY1A3, 
HTRA1, IFNGR1, IGFBP3, 
IL1RN, KIF26A, KRT1, LCN2, 
MAFB, NMU, S100A7, 
SERPINA3, SULT1B1, WNT4 
Cell-cell 
adhesion 
0.065 0.040 AMIGO2, CTGF, ITGA4, 
NRCAM, PCDH20, PPAP2B, 
PVRL3, TGFB2 
CDH16, COL2A1, DSC1, DSC2, 
DSG1, PCDHB10, WNT4 
 
Ratio is the proportion of the annotated genes in the whole gene set.  
Cut-offs used were ≤1/1.5 or ≥1.5 fold, p-value ≤  0.05. 
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CONCLUDING REMARKS 
 
The aim of this thesis was to study the prognostic value of HuR in breast cancer and to 
investigate how HuR facilitates malignant behavior. Understanding the role of HuR in 
carcinogenesis would optimally provide novel targets to treat breast cancer patients. 
 
Cytoplasmic HuR expression was already elevated in ADH, the earliest non-invasive breast 
cancer alteration studied, and the expression remained elevated in DCIS as well in invasive 
cancers. Cytoplasmic HuR expression associated with the more aggressive form of the disease 
in DCIS, i.e. high grade and microinvasive or axillary node-positive findings. In sporadic and 
familial non-BRCA1/2 related breast cancer cases, cytoplasmic HuR expression proved an 
independent marker of reduced survival. Additionally, subgroup analysis of the invasive 
ductal breast cancer specimens showed that cytoplasmic HuR expression associated with 
reduced survival in small tumor size and lymph node-negative patients in whom the need for 
prognostication is great. These data suggest that cytoplasmic HuR expression plays a role in 
breast carcinogenesis and could be useful in clinics to predict disease prognosis.  
 
HuR silencing led to reduction in anchorage-independent cell growth, to increased 
programmed cell death, and to decreased invasion of the cells, suggesting that HuR is 
oncogenic and facilitates carcinogenesis in the breast. Global gene expression analysis 
showed HuR regulation to be extensive and to affect diverse cancer development-related 
pathways. HuR-mediated gene regulation means for the cancer cell a rapid and efficient 
method to alter that cell’s microenvironment to become preferable for cancer development. 
Additionally, we identified two novel target transcripts (CTGF and RAB31) for HuR. 
 
In conclusion, HuR plays a role in breast carcinogenesis by participating in processes 
important in cell transformation and invasion, and in programmed cell death, suggesting that 
breast cancer patients could benefit from treatment preventing cytoplasmic HuR expression in 
their cancer cells. Additionally, cytoplasmic expression of HuR could serve in clinics as a 
prognostic marker to predict disease progression. 
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